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ABSTRACT
Monoclonal antibodies have emerged as a promising class of therapeutics for the
treatment of human disease, and in particular human cancer. While multiple mechanisms
contribute to antibody efficacy, the engagement and activation of immune effector cells -
mediated by the interaction of the conserved Fc regions of the antibody with the Fc
gamma receptors (FcyRs) on immune cells - is critical to the efficacy of several. This
thesis describes the engineering of antibody Fc domain interactions with FcyRs, using the'
yeast S. cerevisiae. In an initial step, a microbial system for the production of full-length
antibodies in S. cerevisiae in milligram per liter titers has been developed, which serves
as a platform for the engineering of antibody Fc domains with defined properties. The
presence of a single N-linked glycan on each chain of the antibody Fc, as well as the
specific composition of the glycoforms comprising it, are critical to the binding of the Fc
to FcyRs, and have largely limited the production of therapeutic antibodies to mammalian
expression systems. Using a display system that tethers full-length antibodies on the
surface of yeast, we identify and characterize aglycosylated antibody variants that bind a
subset of the human low-affinity FcyRs, FcyRIIA and Fc'yRIIB, with approximately wild-
type binding affinity and activate immune effector functions in vivo. In a separate
approach, we identify aglycosylated variants that weakly bind a third low-affinity
receptor, FcyRIIIA, and through subsequent engineering generate variants that bind all of
the low-affinity FcyRs with approximately wild-type binding affinity. By decoupling the
function of the antibody from its post-translational processing, these variants have the
potential to open up therapeutic antibody production to a far wider array of expression
systems than currently available. Finally, in parallel work, we use a similar system to
screen for glycosylated Fc variants with improved affinity and specificity for the
activating receptor FcyRIIIA compared to the inhibitory receptor FcyRIIB, properties
which have been hypothesized to lead to more potent antibody therapeutics.
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Title: J.R. Mares Professor of Chemical Engineering and Bioengineering
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Chapter 1. Introduction
Over the past two decades, monoclonal antibodies (mAbs) have emerged as a
promising class of therapeutics for the treatment of human disease, and in particular
cancer (1-3). To date there are 21 FDA-approved antibodies, nine for the treatment of
cancer. In addition, there are over 150 mAbs in various stages of clinical trial, primarily
against oncology targets, a number which has increased steadily in recent years (2). In
cancer treatment, mAbs have been approved for the treatment of breast cancer
(trastuzumab/herceptin), colorectal cancer (bevacizumab/avastin; cetuximab/erbitux;
panitumumab/vectibix), non-Hodgkin's lymphoma (rituximab/rituxan; ibritumomab
tiuxetan/zevalin; tositumomab/bexxar); and acute myelogenous leukemia (gemtuzumab
ozogamicin/mylotarg) and chronic lymphocytic leukemia (alemtuzumab/campath).
These mAbs target a number of cell surface proteins, such as the ErbB family receptor
tyrosine kinases, the EGF receptor (erbitux, vectibix) and ErbB2/Her2 (herceptin);
immune cell associated markers, such as the B-cell expressed CD20 (rituxan, zevalin,
bexxar), the myeloid-expressed CD33 (mylotarg) and lymphocyte-expressed CD52
(campath); as well as the soluble angiogenic factor VEGF (avastin).
Monoclonal antibodies contribute to improved therapeutic outcomes through
several mechanisms, some of which may occur simultaneously during treatment (4). In
one strategy, mAbs can be used to directly alter the signaling properties of a target cell by
interfering with an essential event that triggers aberrant cellular behavior, such as the
binding of a growth factor to a receptor. Here, the competitive binding of a mAb to the
ligand binding site of a receptor (erbitux) or the sequestration of ligand (avastin) serves to
block the signaling event. mAbs have also been used to deliver cytotoxic agents - such
as toxins, radionucleotides, and DNA damaging agents - to tumor cells. Here, the
specificity of mAbs for a tumor-specific antigen is used to distinguish cancerous cells
from healthy cells, in turn delivering an antibody-conjugated cytotoxic payload to the
tumor (zevalin, bexxar, mylotarg). Alternatively, unconjugated ("naked") mAbs have
been used to target tumor-specific antigens and trigger activation of the immune system's
native effector functions - those at work during the body's response to infection in the
antibody-mediated adaptive immune response - to initiate immune cell mediated tumor
clearance (rituxan).
While all of the above mechanisms contribute to therapeutic efficacy, immune
cell activation has been shown to play a critical role, in particular through an mAb's
engagement of Fc gamma receptors (FcyRs) (5). The FcyRs, differentially expressed on
immune cells, bind to the conserved Fc region of immunoglobulin G (IgG) - the most
abundant immunoglobulin (Ig) isotype in serum and the Ig of choice in mAb therapy -
and in immunity act to sense the presence of opsonized antigen. Here, the antibody acts
as a flexible adaptor molecule, marking an antigen of interest (such as, in the case of
mAb therapy, a tumor associated antigen) through the interactions of a diverse set of
antibody variable regions that allow for the recognition of a wide array of targets; and in
a second step, allow for the recruitment of common immune effector pathways through
the recognition of the conserved Fc domain. Of particular interest is antibody-dependent
cellular cytotoxicity (ADCC), which leads to phagocytosis of the bound pathogen and
release of inflammatory mediators (5), and in therapeutic antibodies directed against
tumor-specific antigens, the immune cell mediated killing of antibody-bound tumor cells.
The role of antibodies in immunity, the FcyR family that in part mediates
antibody function, and the physical interaction of the two are discussed in more detail
below, as well as previous efforts at the engineering of this interaction for improved
therapeutic properties.
The role of IgG in immunity
Antibodies play a critical role in the adaptive immune response as soluble
mediators for marking the destruction of specific pathogens, and comprise a key part of
the mechanism in which immunological memory against specific pathogens is achieved.
During infection, engagement of B cell receptors (BCRs) with non-self antigen derived
from a pathogen - together with a co-stimulatory signal initiated during the innate
immune response to infection - leads to the propagation of activated, antigen-binding B
cells. Ultimately, further selection and expansion of activated B cells leads to their
differentiation into memory cells (which allow for long-term immunological memory for
the recognition of a specific antigen) and plasma cells (which produce antibodies, the
soluble form of the BCR). Antibodies circulate and mark the infecting pathogen by
binding to the specific antigen recognized by the activated B cell. These antibody-coated
pathogens are then cleared through one of several mechanisms: direct neutralization, such
as through sequestration of soluble toxins or inhibiting the infection mechanism of a
virus; pathogen opsonization - which occurs when several antibodies bind to multiple
antigens (or multiple copies of a single antigen) expressed on a cell surface such as that
of a bacterium - which leads to phagocytosis and destruction of the pathogen by
recognition of the antibody by immune cells; and activation of the complement cascade,
present during innate immunity, which leads to lysis of the antibody-bound infecting cell.
B cells respond to a wide set of antigens through molecular diversity in their
BCRs, which is generated by the combinatorial rearrangement of multiple gene segments
present in the genome, and further diversity is generated after B cell activation through
somatic hypermutation, leading to BCRs with higher affinity for antigen. Together, these
segments comprise the variable, or V, region of the antibody. While antibodies are
unique in their variable regions, they share common effector pathways that are mediated
by a small set of framework constant regions. These functions are spatially distant in the
"Y-shaped" antibody structure, as one end of the antibody molecule, comprising the two
variable-domain containing Fab arms, binds antigen, while the opposite end, comprising
the Fc domain, which is connected to the two Fab arms by a flexible hinge, interacts with
the immune system.
During activation and maturation, B cells switch the constant regions associated
with the antigen-binding variable regions. There are five different Ig heavy chain
constant region isotypes - IgG, IgM, IgA, IgD, and IgE - and over the course of an
immune response a B cell will typically irreversibly switch to the production of IgG. In
addition, within the IgG isotype there are four subclasses (IgG1, 2, 3, and 4), which reflect
the order of their serum abundance. Most therapeutic mAbs are of human, murine, or
chimeric IgG origin, with the human IgG1 subclass most commonly used in therapy.
The human FcyR family
The human FcyR family, differentially expressed on immune cells, recognizes
IgG primarily in the context of antibody:antigen complexes. The hFcyR family consists
of the activating receptors FcyRI, FcyRIIA, and FcyRIIIA, as well as the inhibitory
receptor FcyRIIB. FcyRI binds Fc with high affinity, and is thought to be occupied by
monomeric IgG, and is thus incapable of binding antibody-bound antigen. Deletion of
FcyRI in murine models has no effect on therapeutic antibody activity, and it is thought
that this FcyR is dispensible for therapeutic efficacy (5). In contrast, FcyRIIA, FcyRIIB,
and FcyRIIIA (the "low affinity FcyRs") bind Fc with weak affinity (micromolar binding
constants), approximately two to three orders of magnitude weaker than FcyRI. These
FcyRs become activated only through multivalent interactions between immune cells and
antibody-coated target cells, and engagement of these receptors is thought to be critical to
therapeutic response.
The extracellular domains of the low-affinity FcyRs share similar two-domain
topologies, folding into highly similar three-dimensional structures. The signaling
properties of the FcyRs are controlled by the presence of cytoplasmic immunoreceptor
tyrosine-based activation motifs (ITAMs) or inhibitory motifs (ITIMs) associated with
the FcyR, either directly linked through the transmembrane domain, in FcyRIIA and
FcyRIIB, or through the association of a common gamma chain, in FcyRIIIA and FcyRI.
The FcyRs become activated through receptor crosslinking, a result of the simultaneous
engagement of multiple IgGs bound to a target antigen. The extracellular domains of
FcyRIIA and FcyRIIB are highly identical (sharing greater than 90% sequence identity),
and intracellularly differ in the presence of an ITIM in FcyRIIB, the lone inhibitory
receptor. In addition, allelic variation exists within both FcyRIIA (which can contain an
Arg or a His at position 131) and FcyRIIIA (which can contain a Val or Phe at position
176) - these variations, located near sites of contact between IgG Fc and FcyR, impact
binding affinity, and in some cases, biological response.
Interactions between IgG and FcyRs
The FcyRs bind to a cleft in the antibody Fc formed by the antibody hinge and the
loops of the CH2 domain (6, 7), making asymmetric contacts with the homodimeric Fc.
In addition to the lower hinge region, three CH2 loops make direct contacts with
receptor: the B/C loop, the C'/E loop, and the F/G loop. The C'/E loop, in addition to
mediating protein-protein interactions, encodes information for an essential post-
translation modification - the addition of a glycan to an asparagine residue (in human
IgG1, at position asparagine 297) - which is thought to allow the Fe to adopt an open
conformation capable of being bound by FcyR (8). Loss of Fe N-linked glycosylation -
either through enzymatic truncation, point mutation, expression in the presence of N-
linked glycosylation inhibitors, or prokaryotic expression - has been shown to ablate
FeyR binding and immune cell activation, leading to the view that N-linked glycosylation
of the IgG Fe is strictly required for activation of immune effector functions. In addition,
the binding of FeyRs, and subsequent biological response, is sensitive to the types of
sugar residues comprising the glycan. For example, the absence of a fucose residue
increases the affinity of FeyRIIIA for Fe, promoting a more potent activating response (9),
while the presence of terminal sialic residues switches the IgG to an anti-inflammatory
mode (10).
The differential engagement of the low-affinity FeyRs - in particular the lone
inhibitory receptor FeyRIIB and the activating receptor FcyRIIIA, the only FeyR
expressed on natural killer cells - has been shown to be important to therapeutic response.
Murine models have shown that lack of the inhibitory signal, or a large preference for
engaging activating receptor over inhibitory receptor, lead to greatly enhanced
therapeutic responses (11, 12), suggesting that the balance of signals coming from the
engagement of activating and inhibitory FeyRs on a given immune cell is a key factor in
antibody potency. In addition to the inhibitory signal, the strength of activating signals
also appears to be important to antibody efficacy. Clinical data of patients treated with
the FDA-approved antibodies rituxan and herceptin have shown a significant correlation
between objective response rate and allelic variation within FcyRIIIA, with patients
homozygous for a valine at position 176 of the receptor, instead of a phenylalanine,
having significantly better outcomes (13-16). The FeyRIIIA 176V allele (FcyRIIIA17 6v)
binds Fc several-fold more tightly than FeyRIIIA 176F, suggesting that the persistence of
engagement of this activating receptor is a key factor in therapeutic outcome. To this end,
numerous approaches have been taken to engineer the interaction of antibody Fc with
FeyR for improved immunotherapy (17).
Implications of antibody N-linked glycosylation to biotechnology
N-linked glycosylation, critical for the recognition of IgG by FcyR, occurs at
asparagine residues within the polypeptide motif Asn-Xaa-Ser/Thr (where Xaa can be
any amino acid except Pro), and is a common feature of the eukaryotic protein folding
and secretory pathway. While the initiation of this post-translational processing is
conserved across eukaryotic organisms, through the attachment of a common core
oligosaccharide to the asparagine residue, the downstream N-linked glycosylation
pathways and processing of the glycan vary widely among eukaryotes, resulting in
widely divergent glycan structures. The human N-linked glycan (depicted in Figure 3.10),
is a branched structure, resulting from the trimming of sugars from the core structure and
subsequent differential addition of terminal galactose and sialic acid residues, as well as a
fucose residue.
Other expression hosts commonly used in biotechnology for the production of
recombinant proteins differ greatly in their glycan processing. The prokaryote E. coli
lacks the N-linked glycosylation machinery, producing aglycosylated proteins; the yeast
S. cerevisiae attaches multiple mannose residues to the core structure, resulting in
hypermannosylation; and the yeast P. pastoris likewise attaches terminal mannose
residues, although without hypermannosylation. In addition to these microbial
expression systems, other expression systems, such as filamentous fungi (terminal
mannose residues), plants (attachment of non-human sugar residues), and insect cells, all
have non-human N-linked glycosylation patterns. In the context of therapeutic antibody
biomanufacture, such variation in the composition of the N-linked glycan - in addition to
altering FcyR binding affinity - can lead to the presence of sugars that are rapidly cleared
and/or immunogenic, greatly decreasing the serum half-life of the mAb. As a result,
production of therapeutic antibodies has largely been limited to mammalian cell lines
capable of attaching human glycans, or more recently, to yeast strains engineered to
allow for humanized glycosylation patterns (18).
Previous approaches to engineering antibody Fc domains
Numerous approaches have been taken to engineer the properties of the antibody
Fc and its interaction with FcyR, in particular with FcyRIIIA, which has been strongly
correlated with objective response. These approaches fall into two classes: altering the
composition of the N-linked glycan attached to the Fc, or altering the characteristics of
the polypeptide chain itself (17). In the glyco-engineering front, human cell lines have
been developed to preferentially express proteins with defucosylated N-linked glycans
(19), which allow for higher affinity binding to FcyRIIIA and more potent receptor
activation; in addition, P. pastoris strains engineered to attach homogeneous populations
of humanized glycoforms to IgG are also capable of eliciting enhanced FcyRIIIA binding
and immune cell activation (18).
Similarly, most efforts to engineer the polypeptide itself have focused on
increasing the binding affinity to FcyRIIIA, and have employed a variety of protein
engineering methods. In one approach, in silico prediction and experimental validation
was used to construct an Fc variant that binds FcyRIIIA with approximately 100-fold
increased affinity (20). Separate approaches have also aimed to selectively increase the
binding affinity to the activating FcyRIIIA compared to inhibitory FcyRIIB (21, 22), or to
the activating FcyRIIA compared to FcyRIIB (23). In one approach, alanine scanning
point mutagenesis was used to comprehensively define Fc positions that contribute to
FcyR specificity, and alanine point mutants combined to generate an Fc variant with
enhanced specificity (21). In a second approach, yeast display of randomly mutated Fc
libraries was used to identify point mutations that both improve binding to FcyRIIIA, as
well as those that impart FcyRIIIA-specific binding, and then mutations combined to
generate a variant Fc that binds FcyRIIIA with approximately 10-fold increased affinity
but imparts little change in binding affinity to FcyRIIB (22).
Summary of thesis work
In the following chapters, I describe the production and engineering of antibodies
and antibody constant domains in the yeast S. cerevisiae. Chapter 2 describes a microbial
system for the production of full-length antibodies in S. cerevisiae, achieving yields of
secreted antibody approximately 200-fold greater than those previously reported for this
yeast. In addition to enabling the laboratory-scale production of IgGs in low milligram
per liter titers, this system also serves as a platform for the engineering of antibody Fc
domains with defined properties, outlined in Chapters 3 through 5. A shortcoming of our
yeast expression system, and in general any microbial or non-human therapeutic antibody
expression system, is the inability of the host organism to place native N-linked glycans
on the Fc of the IgG. The presence of the N-linked glycan, as well as the specific
composition of the glycoforms comprising it, is critical to the binding of the Fc to FcyRs
on immune cells and subsequent immune cell activation. Thus, decoupling this binding
event from the post-translational processing of the antibody should allow for the
production of therapeutic antibodies in expression systems not currently accessible for
antibody biomanufacture. In Chapter 3, I describe the identification of aglycosylated
antibody variants that bind a subset of the human low-affinity FcyRs, FcyRIIA and
FcyRIIB, with approximately wild-type binding affinity and activate immune effector
functions in vivo. Building upon this work, Chapter 4 describes the engineering of
aglycosylated Fc variants that bind all of the low-affinity FcyRs with approximately wild-
type binding affinity. Finally, Chapter 5 addresses another challenge in antibody Fc
engineering, the engineering of binding specificity between activating and inhibitory
receptors, which has been hypothesized to lead to more potent antibody therapeutics.
Chapter 2. Secretion of full-length IgG from S. cerevisiae I
Introduction
The expression of heterologous proteins in microorganisms has long facilitated
the detailed characterization as well as biotechnological use of many proteins of interest.
Expression in hosts such as the bacterium Escherichia coli and the yeast Saccharomyces
cerevisiae offer several advantages, such as fast doubling times, high cell densities,
inexpensive cell culture and fermentation requirements, and well-characterized and easily
manipulatable genomes, making them highly accessible and productive systems.
Eukaryotic expression hosts offer the advantages of the eukaryotic protein folding
machinery, oxidative folding environment, and ability to attach N-linked glycans, a
common post-translational modification of eukaryotic proteins; S. cerevisiae in particular
is an extremely well characterized model organism, with much known about its genetics
and biochemistry.
Of particular interest to the biotechnology community is the expression of
immunoglobulins, a class of molecules utilized in immunity for the recognition and
subsequent clearance of pathogens. The advent of hybridoma technology (24) enabled
the production and characterization of monoclonal antibodies, a modality that has rapidly
become a platform of choice to specifically recognize myriad therapeutic targets, and in
particular oncology targets (2). In addition, the specific recognition of proteins of interest
conferred by antibodies has led to their widespread use as all-purpose reagents in
laboratory settings, enabling an array of immunoassays.
While antibody fragments such as scFvs and Fabs have been efficiently produced
in microbial expression systems, the expression of fully-assembled immunoglobulins in
microbial expression systems has met with more modest success. In E. coli, Simmons
and coworkers achieved ~ 100 mg/L titers under fermentation conditions, by developing
a dual cistron system for controlling the mRNA levels of heavy and light chain transcripts,
which was found to greatly affect the yield of fully-assembled antibody (25). More
1 Portions of this chapter are adapted from a manuscript under review, "Directed Evoluiton of a Secretory
Leader for the Improved Expression of Heterologous Proteins and Full-Length Antibodies in S. cerevisiae",
J. Andy Rakestraw*, Stephen L. Sazinsky*, Andrea Piatesi, Eugene Antipov, and K. Dane Wittrup.
recently, Mazor and coworkers reported a dicistronic system that allows for ~ 0.2 - 1
mg/L expression in shake flask culture (26)
Less progress has been made in the secretion of fully-assembled immunoglobulins
from S. cerevisiae, which has not been shown to secrete full-length IgG in titers sufficient
for use as an expression host (27). Wood and coworkers reported the intracellular
accumulation of low levels of IgM (28), and later, Horwitz and coworkers reported the
secretion and purification of fully-assembled human IgG, at yields of approximately 50
gg/L in 5 mL shake flask culture (29). Other yeasts, such as Pichia pastoris (30) and
filamentous fungi (31) have met with more success, with yields up to 30 mg/L reported
for P. pastoris and 900 mg/L for Aspergillus niger.
Such reports suggest that there is further capacity for IgG expression from S.
cerevisiae, and here we ask whether IgG secretion from S. cerevisiae can be improved by
altering the properties of the signal sequence that directs the movement of the IgG heavy
and light chains as they transit through the secretory pathway. Mutant signal sequences,
based upon the wild-type alpha mating factor 1 leader peptide (MFalpp) commonly used
to direct the secretion of heterologous proteins from yeast (32, 33) were previously
identified using a directed evolution approach, utilizing a cell surface secretion assay
(CeSSA) that allows for the quantitative enrichment of surface captured target protein
reflective of the true secretion properties of an individual variant (34). The screen
identified several MFalpp variants that improve the secretion of a model scFv, 4m5.3, in
some cases up to 16-fold (35). These leaders direct the improved secretion of additional
scFvs and the structurally unrelated proteins HRP and an IL-2 variant, from two- to five-
fold (35).
Below, we show that the combination of leader sequence evolution as well as
engineering of the host strain leads to the secretion of fully-assembled IgG in low mg/L
titers, an approximately 200-fold improvement over previously reported yields (29). In
the process, we characterize the IgG secreted from S. cerevisiae, highlighting some of the
challenges in using this expression host.
Results
Construction of S. cerevisiae hIgG1 secretion vectors. The yeast IgG secretion vectors,
created by Andy Rakestraw, are detailed in his thesis (35). Briefly, the human IgG1
heavy chain and human kappa light chain were cloned out of the vector 6-23 IgG (36), a
derivative of the mammalian hIgG1 secretion vector pPNL501 (generous gift of Michael
Feldhaus, formerly of Pacific Northwest National Labs), and placed in front of the
galactose inducible GAL10 promoter and alpha terminator on the auxotrophic shuttle
vectors, pRS316 and pRS314 (37), respectively. To direct the secretion of the
polypeptide, the wild-type alpha-factor pre-pro signal sequence (MFalpp), as well as the
evolved versions app8 and appS4 (35), were placed in front of the heavy and light chains.
The heavy chain secretion vector contains unique MluI and NheI restriction sites for
variable domain cloning; the light chain secretion vector contains unique NheI and BsiWI
sites for variable domain cloning, as well an N-terminal FLAG epitope tag following the
secretion signal and Kex2 Lys-Arg cleavage site, for characterization and purification.
Initial secretion of IgG from S. cerevisiae. As an initial model system for hIgG1
secretion from S. cerevisiae, the 4m5.3 variable domains (38) were cloned into the yeast
secretion vectors, co-transformed into BJ5464a and the PDI-overexpressing derivative
YVH10 (39), and assayed for their ability to direct IgG secretion. Yeast cell culture
supernatants of app8- and appS4-led 4m5.3 IgG displayed large (low mg/L) secretion
yields by fluorescein quench titration assay (Andy Rakestraw, unpublished results), yet
sequential Protein A and FLAG purification yielded little purified IgG (Andy Rakestraw,
unpublished results), suggesting the presence of relatively large amounts of antibody, but
not in a purifiable format.
The data suggest the presence of functional antibody variable domains, yet non-
functional or non-assembled constant domains. Western blots of yeast culture
supernatants confirm this hypothesis (Figure 2.1). Anti-Fc (polyclonal) blotting under
reducing conditions reveals distinct heavy chain bands, with two bands displaying
mobility approximately that of a hIgG1 kappa control, and two additional bands present
with much faster mobility, at approximately 30 kDa (fragment 1) and 10 kDa (fragment
2). The presence of these smaller, anti-Fc reactive bands suggests that the heavy chain is
proteolyzed during the secretion process.
To confirm heavy chain proteolysis, as well as characterize the fragments present
during secretion, 4m5.3 IgG was freshly secreted and purified with an anti-Fc polyclonal
antibody, and bands present from the purified protein subjected to N-terminal sequencing.
N-terminal sequencing of the two lower molecular weight bands revealed the following
mixture of N-termini:
Fragment #1: KVEPKS
Fragment #2: TISKAKG, AKGQPRE
When mapped to the hlgG1 sequence, these fragments suggest proteolysis after lysine
residues at positions K213, K334, and K338 (Figure 2.2), and give expected fragment
molecular weights of 26.3 kDa (234 amino acids), 12.7 kDa (113 a.a.), and 12.3 kDa (109
a.a.). K213 is located at the C-terminal end of the heavy chain CHI domain, adjacent to
the hinge region; K334 and K338 are located in the CH2 domain, near the CH2-CH3
domain interface (Figure 2.2). Given their location near relatively flexible regions of the
IgG structure, it's possible that these sites represent protease accessible regions of the
heavy chain.
Approaches to limiting heavy chain proteolysis. Experiments using control hIgG1,
treated with or without reduction with DTT and/or with and without boiling to denature
the polypeptide, reveal that proteolysis likely does not occur after secretion of IgG into
the cell culture supernatant, but intracellularly, as no heavy chain degradation products
are present during the secretion of an irrelevant control protein (data not shown). To
limit or eliminate proteolysis during the secretion process, as well as test the hypothesis
of site-specific, enzymatic proteolysis, a series of lysine to alanine point mutants were
constructed and analyzed by anti-Fc Western blotting (Figure 2.3). K334A alone does
not eliminate the ~10 kDa molecular weight band, as well as an -40 kDa band that likely
represents heavy chain residues 1-333 and 1-337, yet K334A/K338A appears to remove
both of these bands (Figure 2.3b), consistent with the N-terminal sequencing data.
Interestingly, K213A/K214A alone does not limit proteolysis, but the quadruple mutant
K205A/K21OA/K213A/K214A does, suggesting that other nearby sites contribute to
cleavage (Figure 2.3a). Given the presence of multiple lysine residues flanking K213,
we asked which combinations of alanine mutations would block proteolysis. The
minimal mutant, K21OA/K213A, limits the presence of the ~ 30 kDa band, suggesting
that this double mutant could alter protease recognition (Figure 2.3b). Secretion of the
quadruple mutant K21OA/K213A/K334A/K338A, which combines the minimal motifs at
both protease sites, yields full-length IgG under non-reducing conditions (Figure 2.3c).
Thus, removal of specific lysines limits proteolysis, although in the process appears to
reduce secretion yields, as evidenced by the faint bands present (compare Figure 2.3c to
Figure 2.6, left, with equivalent loading standards).
As an orthogonal approach, a search of known S. cerevisiae endoproteases
pointed to a family of enzymes, the yapsins, which cleave after mono- and dibasic
residues (40, 41). Much precedent exists for the unintended action of yapsin proteases in
the secretion of heterologous proteins from yeast, in particular implicating the enzymes
ypsl and yps2 (42-45). To probe the hypothesized role of the yapsins in proteolysis, as
well as potentially create an improved strain for the secretion of full-length IgG, the
single yapsin deletions AYPS1, AYPS2, and AYPS3 were constructed in the parent
YVH10 strain, through homologous recombination of a kanmx cassette into the native
YPS genes, and assessed for the extent of heavy chain proteolysis during 4m5.3 IgG
secretion (Figure 2.4). IgG secretion from all deletion strains does not vary significantly
than that from the wild-type strain, as similar, lower molecular weight anti-Fc reactive
bands are present for secretion from all strains.
In addition to altering the characteristics of the polypeptide and the strain, the
effect of induction temperature upon proteolysis was assessed (Figure 2.5). Interestingly,
and fortuitously, there is a strong correlation between induction temperature and
proteolysis, with almost complete proteolysis occurring at 37 'C induction, substantial
proteolysis occurring at 30 'C induction (the standard induction temperature used in the
above experiments), and limited proteolysis at 20 *C. At 20 *C induction, reducing and
non-reducing anti-Fc and anti-FLAG Western blots show the presence of fully-assembled
hIgGi with limited proteolysis (Figure 2.6). Interestingly, for 4m5.3, the light chain is
secreted in vast excess over the heavy chain, as evidenced by a faint high molecular
weight band of fully-assembled IgG present in the anti-FLAG blot, compared to the
intense lower molecular weight band (free light chain monomer) and the - 50 kDa band
(light chain dimer) (Figure 2.6, right). This is perhaps a feature of microbial expression
of antibody chains, as a vast excess of light chain was also observed during E. coli
expression (25).
Characterization of S. cerevisiae secreted IgG. To characterize the yeast-secreted IgG,
4m5.3 hIgG1 was expressed in 1 L shake flask culture and purified. Protein gels of
protein A and FLAG-purified supernatant show a band consistent in size with a full-
length human IgG1 (Figure 2.7). Additional, smaller molecular weight bands consisting
of partially assembled IgG are also purified. When reduced with DTT, the IgG bands
collapse into a 30 kDa light chain band and two Fc-containing bands at approximately 50
kDa. Treating the IgG with the N-glycosidase EndoH results in a slight increase in the
mobility of both heavy chain bands. The new mobility is consistent with that of the
DTT-reduced, non-N-glycosylated 4m5.3 N297Q mutant, which removes the lone N-
linked glycosylation site in hIgG1, demonstrating that the fully assembled IgG contains
N-linked Fc glycosylation. Further treatment of the IgG with mannosidase causes the
upper heavy chain band to collapse into the lower band, suggesting that a subpopulation
of the secreted heavy chain has some O-linked glycosylation in addition to the typical N-
linked Fc glycosylation. N-terminal sequencing of the upper and lower heavy chain
bands were both consistent with proper signal sequence cleavage (data not shown),
eliminating this as a possible explanation for the differences in mobility. It also appears
that some higher molecular weight N-linked glycosylated protein is present (lanes 6 and
8), likely indicative of uncleaved, glycosylated, leader peptide.
4m5.3 IgG secretion was further enhanced through manipulation of the host strain.
IgG secretion directed by the app8 and appS4 leaders was compared to the wild-type
leader with and without the overexpression of protein disulfide isomerase (PDI), a
chaperone previously shown to be beneficial to scFv expression (Figure 2.8) (39, 46).
The improved leaders, in combination with PDI, enhanced IgG secretion 50-fold over the
wild-type leader alone, with about 25-fold of that improvement due to the mutant leaders.
In previous studies, it has been shown that heterologous protein expression can put
significant negative selection pressure on low-copy plasmid retention resulting in a
substantial subpopulation of cells to be plasmid negative (47, 48). To compensate for
expression instability caused by the dual plasmid system, chromosomal integrations of
the two genes were made resulting in an additional four-fold improvement in secretion.
The total yield of 4m5.3 IgG secreted from the enhanced expression strain in five mL
culture was determined to be approximately 9 mg/L by fluorescein quench assay and
quantitative Western blotting. The total yield of a one-liter shake flask culture after
protein A and FLAG purification was determined to be approximately 1.5 mg/L.
Combined, these strategies impart a 200-fold improvement in IgG secretion over the
native leader alone making S. cerevisiae a productive host for the expression of full-
length IgG.
To test IgG functionality and specificity, the heavy and light chains of the 4m5.3
IgG were reformatted to express the anti-EGFR antibody 225 as well as the anti-CEA
antibody sm3E as hIgG1 chimeras (Figure 2.9). Antibody titers for 225 and sm3E in 1 L
cultures were similar to or better than the yields derived for 4m5.3 expression. The 4m5.3
IgG binds strongly and specifically to yeast cells labeled with fluorescein. The yeast-
produced 225 IgG binds to the EGFR expressing A431 cell line and is competed off
when cells are pre-incubated with murine 225 or when the IgG is pre-incubated with
soluble 404SG, a yeast produced version of the extracellular domain of EGFR,
demonstrating antigen specificity. Similarly, the sm3E IgG labels the CEA-expressing
LS174T cell line and can be competed off with sm3E scFv. Functional expression of
these three antibodies, derived from different mouse variable genes, and in some cases
further altered by humanization and affinity maturation, suggests that this system can
robustly express full-length antibodies regardless of their family or origin.
Discussion
Through a combination of leader sequence engineering and secretion optimization,
we demonstrate that S. cerevisiae can be used as a host for the expression of fully-
assembled IgG in milligram per liter titers, making it an accessible laboratory-scale tool
for antibody production. Such a system may enable the rapid production of reagents, the
engineering and characterization of antibodies of interest, or, as described in subsequent
chapters, serve as a platform for the high-throughput engineering of antibody Fc domains
with desired properties.
The yields we see represent an approximately 200-fold improvement over
previously reported IgG secretion yields from S. cerevisiae (29), and come from a variety
of sources. By far the greatest source of improvement is imparted by the mutant leaders
themselves, which account for an approximately 25-fold improvement. Over-expression
of protein disulfide isomerase, which has previously been shown to improve the
expression of disulfide-containing proteins (39) and immunoglobulin-derived scFvs (46),
contributes about a two-fold increase. Finally, chromosomal integration of the heavy
chain and light chain open reading frames (ORFs) accounts for an additional four-fold
increase. The contribution of signal sequence engineering alone highlights the success of
this approach, and points to its potential as a tool that can be used alongside, or in the
case of our work, in conjunction with traditional approaches to protein expression
improvement, which typically consist of host strain manipulation.
While we have achieved vast improvements in the secretion of fully-assembled
IgG from S. cerevisiae - in terms of yield, quantified at approximately two orders of
magnitude - there is still substantial room for improvement in this system. In particular,
proteolysis of the antibody heavy chain, while dramatically reduced, still greatly reduces
yield. Purification of yeast-secreted IgG from 1 L shake flask culture has shown that
only approximately 25% of the Protein A purified protein can also be FLAG purified
(data not shown), likely due to both proteolysis and the presence of unassembled heavy
and light chains. While constructing alanine point mutants at likely protease sites limits
proteolysis, it also appears to have generated mutations that reduce secretion, likely
offsetting the gains in yield due to improved processing. A better strategy will likely be
through strain manipulation, through identifying and deleting candidate proteases, which
also has the advantage of maintaining the native IgG polypeptide sequence. Our initial
look at the yapsin family did not identify any single gene deletions that limited
proteolysis, although it's possible that yapsin family members could still be the
proteolytic agent(s), as members of this family have overlapping substrate specificities
(41, 43), and thus a strain with multiple yapsin deletions could allow for non-proteolyzed
heavy chain secretion. Another possibility is that IgG secretion leads to elevated stress in
S. cerevisiae, and finding expression conditions that limit stress may solve the dual
problems of heavy chain proteolysis and O-linked mannosylation.
As constructed, our system is most suitable as a laboratory scale tool for the
production or engineering of IgGs. In addition to proteolysis and overall yield, the
largest hurdle in becoming a viable alternative for therapeutic antibody production is
glycosylation. The binding of antibody Fc domains to Fcy receptors (FcyRs) is highly
sensitive to the presence of a single N-linked glycan on the antibody Fc, and while
eukaryotes share a core glycan structure, the nature of the sugars attached to this core
structure varies widely across organisms. S. cerevisiae hypermannosylates N-linked
glycans (49, 50), producing a highly variable structure that almost certainly has different
FcyR binding properties. In addition, terminal mannose residues, such as those present in
typical yeast N-linked glycans, as well the O-linked glycans present on a sub-population
of the heavy chains we see, are recognized by mannose receptors and rapidly cleared, and
would dramatically reduce the circulation half-time of a yeast-secreted therapeutic
antibody. To this end, major efforts have been undertaken to glyco-engineer the yeast P.
pastoris, resulting in strains with humanized glycosylation patterns (51-54), and in
particular for IgG (18). An alternative approach, described in Chapters 3 and 4, would be
to develop aglycosylated variants of the IgG Fc in which the function of the Fc (to elicit
immune effector functions) is decoupled from its post-translation processing.
Materials and Methods
hIgG1 yeast secretion vector construction (35). The human IgG1 constant heavy chain
was PCR amplified from vector 6-23 IgG (55), a derivative of the human IgG1 kappa
expression vector pPNL501 (generous gift of Michael Feldhaus) introducing Mlul and
XhoI sites on the 5' and 3' ends respectively. The heavy chain was then subcloned into
the vector WTappD1.3 using the MluI and XhoI subcloning sites. The 4m5.3 variable
region was PCR amplified from WTappF4m5.3 with primers introducing Mlul and NheI
sites with which it was subcloned into the new heavy chain vector. The light chain was
PCR amplified from 6-23 introducing 5' and 3' NheI and XhoI restriction sites
respectively which were used for subcloning into the WTapp4m5.3 vector to make the 6-
23 light chain yeast vector. The 4m5.3 variable light chain region was amplified from
WTappF4m5.3 using primers introducing NheI and BsiWI sites used to subclone the VL
behind the WT prepro. Mutant prepro leaders were inserted by amplifying the leaders
introducing SphI and NheI sites and cloning them in front of the IgG heavy or light chain
ORF.
Small-scale secretion of IgG for characterization of cell culture supernatants. 4m5.3
containing heavy and light chain vectors were transformed into YVH10 and selected for
growth on SD-CAA plates (2% glucose, 0.67% yeast nitrogen base, 0.54% Na2HPO4,
0.86% NaH2PO 4-H2 0, 0.5% casein amino acids, plus 1.5% agar). A single colony was
inoculated into 5 ml SD-CAA, pH 6.0 and grown overnight at 30'C until saturation
(OD 600 ~ 5). Upon saturation (OD 600 ~ 5), cells were pelleted and resuspended in 5 mL
of phosphate buffered YPG, pH 6.0 (2% galactose, 2% peptone, 1% yeast extract, 0.54%
Na2HPO 4, 0.86% NaH2PO 4 H2O) and allowed to secrete for 72 hrs at a given induction
temperature. Cell culture supernatants were harvested by centrifugation, and either
directly assayed or stored at 4 *C until assayed.
For integration strains, the heavy and light chain ORFs were subcloned into
pRS304 and pRS306, respectively, with KpnI and Sac digests. Five micrograms of
vector were linearized by restriction digest and transformed into BJ5464a or YVH10
using electroporation, and selected for growth on SD-CAA plates.
Western blotting. For a given analysis, equal volumes of cell culture supernatant were
loaded onto 12% bis-tris gels (Invitrogen) and resolved by SDS-PAGE in MOPS running
buffer (Invitrogen). Proteins were transferred to nitrocellulose (BioRad), blocked with
5% dried milk in TBS plus 0.1% Tween 20 (TBST), and probed with a 1:2000 dilution of
anti-Fc HRP (Pierce) or 1:3000 anti-FLAG HRP (Sigma). Blots were incubated with the
Pierce West Dura luminescent substrate (Pierce) and imaged on a FluorS Imager
(BioRad).
N-terminal sequencing. Wild-type 4m5.3 hIgG1 was secreted from YVH10 in 1 L
shake flask culture, under similar conditions as described above, and allowed to secrete
for 72 hrs at 30'C. Cell culture supernatant was clarified by centrifugation followed by
vacuum filtration, then concentrated and exchanged into PBS, pH 7.4. IgG was purified
from concentrated supernatant by an anti-Fc polyclonal antibody conjugated to agarose
(Sigma).
5 pg of total purified protein was resolved by SDS-PAGE (described above) and
transferred to PVDF (BioRad). PVDF was incubated for 5 min with Coomassie dye,
destained with three exchanges of Coomassie destain solution for 60 min each, then
washed five times with ddH20. Upon drying, individual bands were excised from the
PVDF blot and submitted for seven cycles of N-terminal sequencing analysis (Tufts
University Core Facility).
Construction of hIgG1 point mutants. Site-directed mutagenesis was performed by
PCR amplifying the entire mutant plasmid using complementary primers containing the
desired point mutations in a 50 1d reaction, using Pfu Turbo polymerase (Stratagene).
The amplification was digested with one microliter of DpnI (New England Biolabs), and
two microliters were transformed into 50 microliters XL-1 Blue Supercompetent E. coli
(Stratagene), and selected for growth on LB plates supplemented with 100 gg/ml
ampicillin. The transformants were then sequenced to confirm the desired mutations.
YPS Chromosomal Deletions. The deletion strategy is an antibiotic cassette disruption
technique based on previously described protocols (56). The KanMX gene conferring
G418 resistance to yeast was amplified from the appropriate S. cerevisiae deletion strain
(Open Biosystems) by PCR with intergenic primers that allow for greater than 200 bases
of homology to the target gene on the 5' and 3' ends. The PCR product was then
transformed into YVH10 by electroporation, where the cassette inserts itself into the
target site on the chromosome by homologous recombination. Transformants were then
selected by growth on YPD plates containing G418 (Gibco). The location of the
integration was confirmed by colony PCR using one primer with homology to sequence
just outside of the insertion site and one primer with homology to the KanMX insertion
cassette, as well as by the absence of a PCR product using one primer with homology to
sequence just outside the insertion site and one primer with homology to the native gene.
Expression and purification of 4m5.3 hIgGi. Wild-type 4m5.3 or 4m5.3 N297Q
containing heavy and light chain vectors were transformed into either YVH10 or the PDI
and BiP over-expressing strain HBiPPDI (57) (generous gift of Anne Robinson,
University of Delaware) and selected for growth on SD-CAA plates. A single colony
was inoculated into 5 ml SD-CAA and grown overnight at 30 'C until saturation (OD 600
~ 5), and then used to inoculate 1 L of SD-CAA in a shake flask at 30 'C for ~ 24 hrs.
Upon saturation (OD 600 ~ 5), cells were pelleted and resuspended in 1 L of phosphate
buffered YPG and allowed to secrete for 72 hrs at 20 'C. Cell culture supernatant was
clarified by centrifugation followed by vacuum filtration, then concentrated and
exchanged into PBS, pH 7.4. IgG was purified from concentrated supernatant by Protein
A (Pierce) followed by anti-FLAG (Sigma) affinity chromatography.
For characterization of IgG glycosylation, 50 pg of purified IgG was treated with
EndoH (New England Biolabs) and/or jack bean mannosidase (Prozyme), then re-
purified with Protein A agarose (Pierce).
Cloning of 225 and sm3E as hIgG1 chimeras. The 225 variable regions were PCR-
amplified from the yeast surface display vector pCT-225, expressing 225 as a scFv (225
scFv DNA generously provided by Winfried Wels). The oligos 5-
agtcacacgcgtcaggtacaactgaagcagtcagg and 5'-tcatacgctagcagcggaaacggtgaccagggtcccttgg
were used to amplify the 225 Vh with 5' and 3' MluI and NheI sites for ligation into the
hIgGi heavy chain backbone; the oligos 5'-caacgtgctagcgacatcctgctgacccagtctccag and
5'-atgtaccgtacgtttgagctccagcttggtcccagc were used to amplify the 225 VI with 5' and 3'
NheI and BsiWI sites for ligation into the light chain backbone. Similarly, the sm3E
variable regions were PCR-amplified from the yeast secretion vector sm3E-His,
expressing a His 6-tag fusion of the sm3E scFv.
Flow cytometric analysis of IgG labeling. 1 x 107 YVH1O cells were washed three
times with 500 p1 carbonate buffer (4.2% NaHCO 3 and 0.034% NaCO 3, pH 8.4),
incubated for 30 min with either 4 pg/g1 NHS-PEG-fluorescein or NHS-PEG-biotin
(Nektar), and then washed three times with 1000 p1 PBS/BSA. Fluorescein-labeled yeast
were then incubated with 10 pg/ml 4m5.3 hIgGI or a hIgG1 kappa polyclonal control
antibody (Sigma) for 60 min at room temperature, washed, and then labeled with a 1:100
dilution of goat anti-human phycoerythrin conjugate (Rockland) for 30 min on ice. For
competition experiments, 10 gg/ml 4m5.3 hIgGi was pre-incubated with 10 pM
fluorescein (Pierce) for 60 min at room temperature, and the mixture then incubated with
fluorescein-labeled yeast.
Prior to labeling, A43 1NS cells (ATCC; kind gift of Jennifer Cochran), a
derivative of the EGFR-overexpressing epidermoid carcinoma cell line A431 (58) were
maintained in DMEM plus 10% FBS. At approximately 80% confluency, cells were
trypsinized, washed three times with ice cold PBS/BSA, and counted on a
hemocytometer. 2 x 105 cells were incubated with 5 Rg/ml yeast-produced 225 hIgG1 or
hIgGi kappa control antibody for 60 min on ice, washed, and then labeled with a 1:100
dilution of goat anti-human PE for 30 min on ice. For competition experiments, 5 jg/ml
yeast-produced 225 hIgGi was pre-incubated with either 1 pM EGFR ectodomain
(404SG) (59) for 60 min on ice, and the mixture then incubated with A431NS cells; or,
A431NS cells were pre-incubated with 50 jig/ml commercial murine 225 IgG (Lab
Vision) for 60 min on ice, and then the yeast-produced 225 IgG added to a final
concentration of 5 pg/ml and 25 pg/ml murine 225 IgG.
Prior to labeling, LS174T cells (ATCC), a CEA-overexpressing colorectal
adenocarcinoma cell line, were maintained in MEM supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. At approximately 80% confluency, cells were
trypsinized, washed three times with ice cold PBS/BSA, and counted on a
hemocytometer. 2 x 105 cells were incubated with 10 nM yeast-produced sm3E hIgG1 or
hIgG1 kappa control antibody for 60 min on ice, washed, and then labeled with a 1:100
dilution of goat anti-human PE for 30 min on ice. For competition experiments, 200 nM
sm3E scFv was pre-incubated with LS174T cells for 60 min on ice, then sm3E IgG added
to a final concentration of 10 nM and 100 nM scFv.
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Anti-Fc Western blot of yeast-secreted 4m5.3 IgG. Yeast cell culture supernatants of app8-led
4m5.3 IgG were analyzed by anti-Fc Western blotting under reducing conditions, with and
without the addition of the N-linked glycosidase EndoH. Abbreviations: hIgG1 (human IgG1
standard), WT (wild-type 4m5.3 IgG), +EA (addition of a Glu-Ala spacer following the Lys-Arg
Kex2 cleavage site at the C-terminus of the signal sequence), N297Q (non-N-glycosylated 4m5.3
N297Q point mutant), control (irrelevant protein secreted under similar conditions).
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Figure 2.2
N-terminal sequence data mapped to IgG structure. Location of the hypothesized protease
sites within hIgG1 secreted from S. cerevisiae. Lysine residues (red spheres) identified in the
structure directly precede fragments identified by N-terminal sequencing, and are mapped onto a
crystal structure of full-length hIgG1 (PDB ID: 1HZH). Numbers in parentheses next to amino
acids represent the corresponding fragment submitted for N-terminal sequencing (Figure 2.1).
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Effect of lysine to alanine point mutants upon heavy chain proteolysis. Anti-Fc Western
blotting of wild-type (WT) and lysine to alanine point mutants (designated by residue number) of
yeast-secreted, app8-led 4m5.3 IgG, under reducing (A, B) and non-reducing (C) conditions.
Abbreviations: h~gG1 (human IgG1 standard), CHI-Hinge (fragment corresponding to proteolysis
at the CHI-Hinge interface, at residue K213 in Figure 2.2), CH2-CH3 (fragment corresponding to
proteolysis at the CH2-CH3 interface, at residues K334 and K338 in Figure 2.2).
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Yapsin deletion strains. Reducing anti-Fc Western blotting of wild-type, app8-led 4m5.3 IgG
secreted from YVH10 (WT) and a series of YVH1 0-derived deletion strains of the yapsin family
genes yps1, yps2, and yps3. Numbers below the yapsin gene indicate strains confirmed to have
the correct deletion, and subsequently transformed with the IgG secretion vectors. Abbreviations:
hIgG1 (human IgG1 standard).
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Effect of induction temperature on IgG secretion. Reducing anti-Fc Western blotting of wild-
type, app8-led 4m5.3 IgG secreted from YVH1O at a series of induction temperatures, as
indicated. Abbreviations: hIgGi (human IgG1 standard).
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Analysis of IgG secretion at 20 *C. (Left) anti-Fc Western blotting of yeast-secreted, app8-led
4m5.3 IgG under reducing (+ DTT) and non-reducing (- DTT) conditions. (Right) anti-FLAG
Western blotting of yeast-secreted, app8-led 4m5.3 IgG under reducing (+ DTT) and non-
reducing (- DTT) conditions. Abbreviations: hIgG1 (human IgG1 standard), HC (heavy chain),
LC (light chain), LC2 (light chain dimer), FLAG-BAP (FLAG tagged standard).
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SDS-PAGE of Protein A and FLAG purified 4m5.3 IgG1. Purified IgG was analyzed under
non-reducing (lanes 2-4) and reducing (lanes 5-10) conditions, with and without treatment of the
glycosidases EndoH and mannosidase. Abbreviations: standard (control human IgG1 standard),
WT (wild-type, yeast-secreted 4m5.3 IgG with app8 leader), N297Q (yeast-secreted 4m5.3
N297Q non N-glycosylated mutant with app8 leader).
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Sources of improvement in antibody secretion. The effects of the leader sequence and strain
manipulation upon the secretion of a 4m5.3 IgG1 mouse/human chimera was quantified by
fluorescein quench titration assay. The VH and VL genes were expressed separately on two CEN
plasmids, under the control of the WTapp (WTpp), and transformed into BJ5464a cells or
YVH10 cells, which carry an additional copy of PDI (WTpp/PDI). Effects of the mutant leaders
app8 and appS4 were also assayed in YVH10 (app8/PDI and appS4/PDI). For the app8 leader,
these genes were also integrated (int.) into the chromosomes of YVH10 cells in place of CEN
plasmid expression (app8+PDI+int.).
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Cell labeling of yeast-secreted IgGs. (A) Labeling of fluorescein-conjugated yeast with purified
4m5.3 IgG followed by an anti-human PE-conjugated antibody and analysis by flow cytometry.
A type-matched, non-specific, human IgG1 kappa polyclonal antibody (Hu IgG1 polyclonal) and
cells labeled with biotin (PEG-biotin) instead of fluorescein were used as negative controls. Pre-
incubation of the 4m5.3 IgG with 10 pM fluorescein was also done to demonstrate specificity.
(B) Labeling of the EGFR expressing cell line A43 INS with yeast-produced 225 IgG. Specificity
was determined through competition assays: yeast 225 IgG was pre-incubated with yeast-
produced EGFR ectodomain, 404SG, or the EGFR-expressing cells were pre-labeled with murine
225 IgG. (C) Labeling of the CEA presenting cell line LS174T with sm3E IgG. Specificity was
demonstrated by pre-incubating the cells with the sm3E scFv.
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Chapter 3. Engineering Aglycosylated IgG variants that Productively
Engage Fc gamma Receptors 2
Introduction
Fcy receptor (FcyR) engagement is essential to the function of immunologlobulin
G (IgG) in both immunity (60) and in antibody-based therapy (5, 17). IgGs act as the
adaptor between a pathogen and the immune response by simultaneously binding antigen
through their variable regions and activating an immune response through interaction of
conserved Fc regions with FcyRs on cells of the immune system. The human FcyR
(hFcyR) family consists of the activating receptors FcyRI, FcyRIIA, and FcyRIIIA, and
the inhibitory receptor FcyRIIB. While FcyRI binds IgG with high affinity (nanomolar
binding constants), FcyRIIA, FcyRIIB, and FcyRIIIA bind IgG with micromolar affmity,
becoming activated only via avid multivalent interactions with opsonized antigen (60).
The binding of IgG to FcyR is highly sensitive to the presence of glycosylation at a single
N-linked glycosylation site at asparagine 297 (N297) in its CH2 domain (8, 61), with a
loss of binding to the low-affinity FcyRs observed in N297 point mutants (21, 62),
enzymatic Fc deglycosylation (63), recombinant IgG expression in the presence of the N-
linked glycosylation inhibitor tunicamycin (64), or expression in bacteria (26, 65). In
addition, the nature of the carbohydrate attached to N297 modulates the affinity of the
FcyR interaction (9, 10). The sensitivity of FcyR binding to specific glycoforms has
limited therapeutic antibody biomanufacture to mammalian expression systems, and has
led to the development of glycosylation-engineered mammalian cell lines (9, 19) and
microbial strains with humanized glycosylation (66) as methods of enhancing antibody
cytotoxicity.
In crystal structures of the complex, FcyR/Fc contact is mediated not only by
protein-protein contacts, but also by specific interactions with the glycan on the Fc that
are proposed to contribute to binding affinity (6, 7). Additional intramolecular contacts
are made between the Fc-linked glycan and residues on the IgG CH2 domain, and it is
2 This chapter has been adapted from: Sazinsky SL, et al. (2008) Aglycosylated Immunoglobulin G1
Variants Productively Engage Activating Fc Receptors. Proc Natl Acad Sci U S A. Copyright 2008
National Academy of Sciences, U.S.A.
thought that these interactions stabilize an open Fc conformation capable of being
engaged by FcyR (8). Successive truncation of an IgG1 glycan results in an incremental
loss of binding affinity (63) and concomitant incremental collapse of the open Fc
conformation (67). However, glycosylation is not strictly required for engagement of all
immunoglobulin receptors with their corresponding Fc ligands, notably in the binding of
IgE Fc to Ig&R (68). Interestingly, the IgE Fc adopts a similar mode of binding to FcR as
the IgG1 Fc in the IgG1 Fc:FcyRIII complex and both receptors and Fcs share structural
similarity (69). In the IgG1 Fc:FcyRIII complex, extensive contacts are made by both
chains of the IgG1 hinge region, with additional receptor contacts made by the B/C loop,
F/G loop, and both sidechains and glycosylation of the C'/E loop of the CH2 domain (6,
7) (Figure 3.1). It is particularly striking that this loop plays a part in receptor recognition
through both direct side chain contacts as well as in encoding information for a critical
post-translational modification.
In the present study, we reasoned that by optimizing the protein-protein
interactions about the C'/E loop:FcyR interface at the expense of glycosylation, we could
identify aglycosylated IgG1 variants that maintain engagement to FcyRs. Here, we
demonstrate that a small subset of substitutions at both N297 and T299 of the
glycosylation motif lead to aglycosylated Fcs that maintain engagement of FcyRs, and in
a particular example are active in vivo. Such aglycosylated antibodies would be facile
templates for further efforts to engineer Fc effector functions and potentially enable a far
wider range of options for therapeutic antibody biomanufacture.
Results
Screening for aglycosylated Fc variants that bind FcyRHIA. To determine if
glycosylation of the Fc was an absolute requirement for FcyR engagement by hIgG1, we
constructed saturation mutagenesis libraries at the Fc C'/E loop and screened them by
displaying the full-length IgG variants on the yeast cell surface (Figure 3.2). In this
display system, the femtomolar affinity fluorescein-binding 4m5.3 single-chain antibody
(38) was reformatted as a hIgG1, allowing 4m5.3 hIgG1 library variants to be captured on
fluorescein-labeled yeast from which they are secreted, by using a cell surface secretion
capture assay (34) in conjunction with an engineered leader sequence that allows for the
improved secretion of fully-assembled hIgG1 from S. cerevisiae [(35); Chapter 2; and
Rakestraw JA, SLS, Piatesi A, Antipov E, & KDW, submitted). Three saturation libraries
centered about the C'/E loop - theoretically encoding all amino acid combinations at
residues 296-299, 297-299, and 297-300 - were pooled and screened for binding to
fluorophore labeled tetramers of a soluble form of the FcyRIIA131R allele by multiple
rounds of fluorescence activated cell sorting (FACS).
Using this screening strategy, in addition to glycosylated variants and the wild
type clone, mutants lacking the canonical Asn-X-Ser/Thr N-linked glycosylation motif
were enriched from the C'/E loop libraries for binding to FcyRIIA (Figure 3.3a). After
two rounds of screening three aglycosylated motifs were identified: the double mutants
S298G/T299A, S298G/T299G, and the single mutant T299A. After a third round of
screening at increased stringency, the sublibrary was dominated by the S298G/T299A
variant, suggesting it as the highest-affinity FcyRIIA binding motif in the library (Figure
3.3b).
To study the contributions of the S298G and T299A mutations to receptor binding,
a series of point mutants were constructed, secreted from yeast, and assayed for their
ability to bind to FcyRIIA 131R (Figure 3.3c). Both the S298G and T299A mutations alone
retain binding to FcyRIIA at comparable or increased levels to wild-type IgG1, and the
S298G mutation in the aglycosylated T299A background yields a variant capable of
binding FcyRIIA to a much greater extent. The S298G/T299A double mutant is incapable
of rescuing binding in the N297Q, N297D, and N297A backgrounds, suggesting there is
a strong requirement for asparagine at position 297 for FcyRIIA binding even in the
absence of conjugated carbohydrate, a finding consistent with its conservation in the
initial library screen.
S298G/T299A is aglycosylated and binds to FcyRs. To confirm that the potential
aglycosylated motifs identified from the yeast-based screen indeed lacked the N-linked
glycan and were capable of engaging FcyRs, wild-type, S298G/T299A, and the non-
receptor binding N297Q aglycosylated control were expressed and purified from HEK
293 cells. Both N297Q and S298G/T299A exhibit increased mobility by reducing SDS-
PAGE (Figure 3.4a) and critically, are not recognized by the mannose-specific lectin
LCA (Figure 3.4b), consistent with the expected absence of N-linked glycosylation.
Surface Plasmon Resonance (SPR) measurements show that S298G/T299A binds to both
FcyRIIA alleles, FcyRIIA131R and FcyRIIA131H, and to FcyRIIB; however, this mutant
does not bind to FcyRIIIA nor the complement component Cl q and binding to FcyRI was
weakened by 10-fold. (Figure 3.4c). S298G/T299A binds FcyRIIA131R with a
dissociation constant (Kd) of 1.7 pM, approximately three-fold stronger than wild-type Fc,
and binds FcyRIIA131H with a Kd of 7.0 ptM, slightly weaker than wild type. A small
increase in affinity compared to wild type for FcyRIIB was also observed, suggesting a
preferential binding of FcyR with an arginine at position 131 (Figure 3.5).
To determine whether S298G/T299A can engage native FcyRs as expressed on
the cell surface, CHO cell lines stably transfected with FcyRIIA 131R, FcyRIIA131H, and
FcyRIIB were labeled with 4m5.3 hIgGI immune complexes (ICs) (Figure 3.4d, and data
not shown). Both wild-type and S298G/T299A IgG ICs label all receptor-expressing
CHO cells in a concentration dependent manner, demonstrating that S298G/T299A binds
FcyRs in this context as well. Consistent with the soluble binding measurements,
S298G/T299A IgG ICs label FcyRIIA131R and FcyRIIB expressing CHO cells at similar
levels as wild type; however, S298G/T299A shows only intermediate labeling of the
FcyRIIA131H allele compared to wild type and the aglycosylated control.
S298G/T299A activates FcyRIIA in vivo. To determine whether this aglycosylated IgG
is functional in vivo, a murine platelet clearance model was used to test the extent of
S298G/T299A activity. The platelet integrin antigen-binding antibody 6A6 was
reformatted as a mouse-human IgG1 chimera and the S298G/T299A mutations
subsequently introduced into the human Fe domain. The antibody was tested in a
transgenic mouse model, in which the endogenous murine FeyRs have been deleted by
gene targeting and the human activation FeyR, hFcyRIIA13 R, is expressed as a transgene,
thus maintaining cell type expression appropriate for the human transgene (70). Mice
with this genotype were treated with wild-type, N297A, and S298G/T299A 6A6 hIgG1
purified from HEK 293 cells and the extent of platelet clearance measured over time
(Figure 3.6). After four hours, S298G/T299A-6A6 treated mice (n=3) showed a
statistically significant drop in platelet count when compared to those treated with
N297A-6A6 or PBS, exhibiting a response that was comparable to wild-type-6A6 and
demonstrating the ability of S298G/T299A to productively engage FcyRIIA in vivo and
result in platelet clearance.
Model of S298G/T299A-FcyRIIA interaction. To explore the structural basis for FcyR
binding of this aglycosylated Fc domain variant, we constructed homology models of
Fc:FcyRIIA complexes based on the previously solved structures of the IgG1 Fc, the
FcyRIIA structure (71) and the Fc:FcyRIII complex (7) (Figure 3.7). Three features
emerge from this modeling. First, in the model of the wild-type interaction, there is only
limited interaction between the two N-linked glycans and FcyRIIA (Figure 3.7a). The
asymmetric nature of the IgG1 Fc: FcyRIIA interaction predicts that the glycan attached
to the B chain of the Fc dimer may interact with residues K 117, T 119, F121, S126, and
F129 of the receptor, whereas the glycan attached to the other chain (the A chain) does
not make contact with FcyRIIA. These glycan:FcyR contacts provide negligible
calculated screened electrostatic intermolecular interactions (approximately zero
kcal/mol), compared to the much larger intramolecular ones between glycan and Fc
[roughly -1.3 kcal/mol, with a dominant contribution from N297/glycan(B)-D265(B)]
and suggest that both oligosaccharides are primarily interacting with their respective Fc
chains. Second, N297 is important for the Fc: FcyRIIA interaction. Aglycosylated N297
has the potential to make hydrogen bond interactions across the interface with S126 of
the receptor (Figure 3.7b). These interactions may be mediated by a bridging water
molecule that can be observed nearby in an unbound FcyRIIA crystal structure (71).
Replacement of N297 with glutamine or alanine disrupts this interaction (and fails to
make similar, stabilizing ones) and is consistent with the observed absence of binding for
such mutants (Figure 3.3c, Figure 3.8a). Interestingly, replacement with aspartic acid
may be able to make a similar interaction, however the greater desolvation penalty of the
charged side chain upon FcyR binding likely results in the reduced binding of this variant.
Finally, the intermolecular interaction between the aglycosylated S298G/T299A
mutant and FcyRIIA includes a salt bridge formed between D265 on the B chain of the Fc
dimer and KI 17 on the FcyR. In the wild-type structure, this interaction is shielded from
solvent by the oligosaccharide chain (Figure 3.7c). In the aglycosylated S298G/T299A
mutant this salt bridge is exposed to the solvent (Figure 3.7d), which nearly halves the
screened electrostatic interaction energy compared to wild type (-5 kcal/mol vs. -10
kcal/mol). However, this effect is more than compensated in the S298G/T299A mutant
by a reduced desolvation penalty (72), a measure of the loss of electrostatic interactions
with solvent upon binding, resulting in an overall stabilized structure. This effect is
illustrated (Figures 3.7e,f) by a reduction in the residual electrostatic potential present on
D265(B) in the mutant compared to the wild-type; similarly, the Figure also shows the
S298G mutation results in a reduced desolvation penalty that contributes to the stability
of the mutant complex. Thus, the predictions made by this homology model provide a
hypothetical mechanism for the stability of the aglycosylated Fc:FcyR complex, resulting
from hydrogen bonding and electrostatic interactions altered in the aglycosylated mutant.
Aglycosylated Fc variants that bind FcyRIHIA. To evaluate the contribution of
individual sidechains in the C'/E loop to FcyR engagement, as well as the nature of the
specificity between FcyRIIA and FcyRIIIA seen in S298G/T299A, we constructed the
full set of single point mutations at positions 297, 298, and 299, and assayed yeast-
secreted IgG variants for binding to both FcyIIA and FcyIIIA (Figure 3.8). Side chain
scanning of 297 and 299 revealed additional mutations that remove the glycosylation
motif but retain residual weak receptor binding: T299H to FcyIIA, and N297D and
N297H to FcyIIIA176V (Figures 3.8a,c-e). T299A is the only aglycosylated mutant
identified that displays dual specificity, exhibiting improved binding to FcyIIA while
retaining moderate binding to the FeyIIIA 176 allele. Interestingly, the nature of the
sidechains at position 299, and not just glycosylation, greatly impacts receptor binding, as
the yeast-expressed glycosylated T299S mutant binds all receptors to a much lesser
extent than the wild-type Fc.
In contrast to positions 297 and 299, where mutations largely disrupt the N-linked
glycosylation motif Asn-X-Ser/Thr, multiple substitutions in a glycosylated Fc
background are tolerated at position 298 (Figure 3.8b). FcyRIIA binding is much more
sensitive to substitution at position 298, with only glycine (S298G) maintaining a level of
binding that is comparable to wild type. In contrast, FcyRIIIA tolerates an array of
substitutions at position 298, and the data highlight potential mutations for engineering
FcyRIIIA vs. FcyRIIA/IIB specificity, such as the previously identified S298A and
S298N mutations (21, 22). Only S298G maintained engagement to both FcyRIIA and
FcyRIIIA in our assay, a finding that taken together with a preference for threonine at 299
(T299) suggests an explanation for the conservation of the motif N-S/G-T in IgG CH2
domains across virtually all species (data not shown).
While our initial efforts focused on FcyRIIA resulted in specificity for FcyRIIA
and FcyRIIB at the expense of FcyRIIIA binding (Figure 3.4c), the sidechain scanning
data suggested that aglycosylated Fcs that bind FcyRIIIA with comparable affinity to
wild type could also be identified. Within the C'/E loop, rational design of double
mutants based upon the weakly FcyRIIIA-binding N297D and N297H substitutions
yielded variants that bound FcyRIIIA 176V at levels 10 to 40% of wild type and with
specificity for FcyRIIIA (Figure 3.9), a desired property in engineering Fcs with
enhanced immune effector functions (17). In a separate strategy, the consensus mutations
K326E, K290E, and K290N - identified in a separate screen for improved FcyRIIA
binding (data not shown) as well as through the efforts of previous groups (22, 73) - were
introduced into the T299A background. Incorporation of the K326E mutation, located at
the base of the F/G loop, led to enhanced binding for FcyRIIIA, approaching wild type
levels for FcyRIIIA176V and weakly binding FcyRIIIA17 6F (Figure 3.9). This result
suggests that additional second-site mutations at contact interfaces other than the C'/E
loop can lead to aglycosylated FcyRIIIA- and FcyRIIA-binding Fcs with a range of
affinities and specificities.
Discussion
Until this study the general knowledge of the binding interaction between IgG and
FcyRs indicates a dependence on the N-linked glycan attached to asparagine 297 on the
IgG heavy chain. The Fc variants described here clearly demonstrate that glycosylation is
not a strict requirement for FcyR engagement, either in vitro or in vivo. In an initial
strategy, by generating aglycosylated Fc variants that bind to FcyRIIA and FcyRIIB we
could demonstrate that the set of mutations necessary to switch from a wild-type
glycosylated binder to a functionally aglycosylated binder is fairly small - in our case it
involved the introduction of only two point mutations. In a second more directed
screening strategy, we could further demonstrate that by introducing additional
modifications into our aglycosylated mutants we can combine features from single
mutants discovered from different screenings, thereby modulating the overall affinity
features of the IgG variant. This combinatorial behavior of the contribution of single
mutations is of special interest for the engineering of IgG variants with very well defined
binding properties.
In addition to the enhanced FcyRIIA13 1R binding observed in the aglycosylated
S298G/T299A variant, we were able to restore binding to FcyRIIIA 176V to near wild-type
levels, suggesting that further engineering can also lead to aglycosylated variants with
wild-type or improved binding to FcyRIIIA. In particular, we anticipate that introducing
mutations into the T299A background, which weakly binds both FcyRIIA and FcyRIIIA,
will lead to fully FcyR competent aglycosylated antibody variants. Building upon these
aglycosylated FcyRIIIA-binding variants will be essential for their potential use as
cytotoxic antibodies, which have emerged as a promising class of therapeutics for
treatment of human cancer in recent years (3). Support for a critical role for FcyR
engagement in the mechanism of anti-tumor activity, and specifically for FcyRIIIA, has
come from three independent studies which found a strong positive correlation between
patient response and the presence of specific alleles of the activating FcyR FcyRIIIA that
conferred enhanced binding for the IgG1 Fc domain of the antibody (13, 15, 16). While
the S298G/T299A variant does not bind complement, the above studies, as well as
murine models that demonstrate a dominant role for FcyR engagement in therapeutic
antibody activity (5), suggest that restoration of complement binding would be
unnecessary for engineered Fc variants. In addition to their ability to bind FcyR, it will
also be important to assess the stability of these variants, as previously characterized Fc
variants (74) and deglycosylated wild-type Fc (75) have displayed reduced thermal
stability.
Given the small number of mutations required to achieve N-linked glycosylation-
independent FcyR binding, it is striking that all naturally occurring IgGs utilize this post-
translational modification nevertheless. Among different antibodies there is variation in
the fucose and galactose-sialic acid attached to the core glycan structure (Figure 3.10),
and it has been reported that these variations dramatically influence the antibody activity.
The absence of fucose in the glycan was reported to enhance the affinity of FcyRIIIA for
IgG up to 50-fold (9) and thereby switching the antibody into an inflammatory mode.
This is required, for example, for cytotoxic antibodies, but also occurs when
autoantibodies generate pathogenic immune complexes and activate autoimmune
cascades. In contrast to fucose, the presence of terminal sialic acid was demonstrated to
be the critical factor for the anti-inflammatory action of high dose IVIG (10, 76). Sialic
acid reduces the affinity of FcyRs to IgG by 5-10 fold (10) and, in addition, marks IgGs
and subsequently allows them to bind to non-FcR lectins (76) and mediate downstream
actions through these novel interactions, resulting in anti-inflammatory responses,
including the upregulation of FcyRIIB on effector macrophages (77). The conservation of
the N-S/G-T glycosylation motif among different species at the expense of this post-
translational variability supports the view that the glycan, although not necessarily
required for FcyR binding, serves as a platform for further modulation of the IgG's
activity, enabling post-translational switching or tuning of the IgG function between an
anti-inflammatory or inflammatory mode.
Finally, our demonstration that IgG variants can be generated that have uncoupled
FcyR binding from N-linked glycosylation opens up new possibilities for protein
engineering and biomanufacture. Our results suggest that receptor binding affinity and
specificity can be engineered on the simpler template of an unmodified polypeptide chain,
and these properties selected for by yeast surface display of aglycosylated Fc mutant
libraries. Such mutants could then be produced in essentially any recombinant
expression system without loss of the desired altered effector functions.
Materials and Methods
Library construction. Libraries were constructed by homologous recombination of a
mutated heavy chain constant region insert into the 4m5.3 heavy chain yeast secretion
vector template according to previously published methods (78). The 4m5.3 heavy chain
secretion vector was previously constructed from the pRS316 shuttle vector by insertion
of the GAL1O promoter and alpha terminator, signal peptide, and 4m5.3 variable heavy
chain domain upstream of the hIgG1 CHI to CH3 constant domains [(35); Chapter 2; and
Rakestraw JA, SLS, Piatesi A, Antipov E, & KDW, submitted).
4m5.3 heavy chain template vector was prepared by digestion with NheI (New
England Biolabs) and XhoI (New England Biolabs), which flank the 5' region of the
hIgGi CHI domain (NheI) and 3' region of the CH3 domain (XhoI). Saturation
mutagenesis of the C'/E loop was performed by gene reconstruction with the
oligonucleotides 297-299NNK (all oligos from Integrated DNA Technologies), 296-
299NNK, and 297-300NNK for each of the three libraries, respectively. In a first PCR
step the mutagenic oligo and reverse primer 4m-CH3-epPCR-rev were used to amplify
the region 5' of the C'/E loop through the 3' region of the CH3 domain, using the wild
type vector as a template. In a second PCR step, this PCR product was used along with
the forward primer 4m-CH1-epPCR-for to amplify the 3' region of the 4m5.3 variable
heavy chain to the 3' end of the CH3 domain, reconstructing the heavy chain CHI to
CH3 gene insert with -50 base pairs of overlap with the digested template vector for
efficient yeast homologous recombination.
Gene inserts were transformed with digested template vector by electroporation
into the yeast strain YVH10/LC, a derivative of the yeast strain YVH10, containing a
chromosomally integrated copy of the 4m5.3 light chain yeast secretion vector. The 296-
299 and 297-300 saturation libraries had ~6xl0 7 transformants, 60-fold greater than their
theoretical diversity at the DNA level (324 ~ 1.0x10 6); the 297-299 library had -4x10 7
transformants.
Oligonucleotides.
297-299NNK (5'-AGCCGCGGGAGGAGCAGTACNNKNNKNNKTACCGTGTGGTCAGCGTCCT)
296-299NNK (5'-CAAAGCCGCGGGAGGAGCAGNNKNNKNNKNNKTACCGTGTGGTCAGCGTCCT)
297-300NNK (5'-AGCCGCGGGAGGAGCAGTACNNKNNKNNKNNKCGTGTGGTCAGCGTCCTCAC)
4m-CH1-epPCR-for (5'-ATGGAATACTTGGGTCAAGGAACCTCAGTCACCGTCTCCGCTAGC)
4m-CH3-epPCR-rev (5'-ATTTTGTTACATCTACACTGTTGTTATCAGATTTCGCTCGAGTCA)
297NNK (5'-CCGCGGGAGGAGCAGTACNNKAGCACGTACCGTGTGGTCAG)
298NNK (5'- GCGGGAGGAGCAGTACAACNNKACGTACCGTGTGGTCAGCG)
299NNK (5'- GGAGGAGCAGTACAACAGCNNKTACCGTGTGGTCAGCGTC)
297NHC (5'- CCGCGGGAGGAGCAGTACNHCAGCACGTACCGTGTGGTCAG)
298NHC (5'- GCGGGAGGAGCAGTACAACNHCACGTACCGTGTGGTCAGCG)
299NHC (5'- GGAGGAGCAGTACAACAGCNHCTACCGTGTGGTCAGCGTC)
N, H, and K encode the following groups of nucleotide bases: N encodes all four
nucleotides; K encodes G and T; H encodes A, C, and T.
Library screening. Library screening was performed using the cell surface secretion
assay (CeSSA) (34). Briefly, libraries were grown in SD-CAA (2% glucose, 0.67% yeast
nitrogen base, 0.54% Na2HPO 4, 0.86% NaH2PO4 H20, 0.5% casein amino acids) at 30 'C
to an OD 600 of - 5, and then induced in YPG (2% galactose, 2% peptone, 1% yeast
extract, 0.54% Na2HPO4, 0.86% NaH2PO 4-H20) for 12 hrs at 20 'C. Following this pre-
induction phase, yeast were labeled with fluorescein-PEG-NHS (Nektar) and re-induced
in YPG containing 15% PEG (w/v) at 20 *C for 36 hrs. Cells were washed with PBS
containing 0.1% (w/v) BSA (PBS/BSA) and labeled with biotinylated hFcyRIIA 131R
preloaded onto streptavidin-Alexa 647 (Invitrogen). The library was sorted on a BD
FACSAria (Becton Dickinson) and collected cells grown in SD-CAA supplemented with
penicillin/streptomycin (Invitrogen), for a total of three rounds of screening. Library
populations were labeled at increasingly stringent concentrations of FcyRIIA tetramer as
follows: round one (50 nM FcyRIIA tetramer), round two (2 nM FcyRIIA tetramer), and
round three (80 pM FcyRIIA tetramer). All clones isolated from screening were re-
transformed into YVH1O/LC and individually assayed for FcyRIIA binding.
Site Directed Mutagenesis. For sidechain scanning of positions 297, 298, and 299,
mutagenesis of the 4m5.3 heavy chain yeast secretion vector was performed using the
Quikchange Multi Site-Directed Mutagenesis Kit (Stratagene) and the degenerate oligos
297NNK, 298NNK, 299NNK, 297NHC, 298NHC, and 299NHC. Clones were identified
and confirmed by subsequent sequencing and re-sequencing. All other point mutants
were constructed by PCR-amplification of the entire vector using complementary primers
containing the desired point mutations.
Characterization of yeast-secreted Fc mutants. Fc mutants freshly transformed into
YVH10/LC were grown in 5 ml SD-CAA at 30 *C until an OD 600 ~ 5, then induced in 5
ml YPG at 20 *C for 72 hrs. Cell culture supernatants were loaded onto fluorescein-
conjugated yeast overnight at 4 *C; yeast were then washed with PBS/BSA, labeled with
10 nM of biotinylated FcyR preloaded onto streptavidin-Alexa 647 at 4 *C for > 2 hrs,
and analyzed by flow cytometry. Labeling with 10 tg/ml Protein A-Alexa 647
(Invitrogen) was performed as a separate IgG loading control for all samples.
Mice. y- FcyRIIB~'~ mice were generated in the Ravetch laboratory, backcrossed for 12
generations to the C57BL/6 background and crossed to hfeyRIIA5 mice (The Jackson
Laboratory, Bar Harbor, ME). Female mice at 2 to 4 months of age were used for the
experiments and maintained at the Rockefeller University animal facility. All
experiments were performed in compliance with federal laws and institutional guidelines
and have been approved by the Rockefeller University (New York).
Cell culture. CHO cells were cultured according to the ATCC guidelines. CHO-
hFcyRIIA13 1H, CHO-hFcyRIIA13 1R and hFcyRIIB were obtained by transfection of the
pCMV-Script-hFcyRIIA13 1H, CHO-hFcyRIIA13lR and hFcyRIIB plasmids and subsequent
selection with 1 mg/ml geneticin (Invitrogen).
Antibodies and recombinant proteins. The 6A6-human Fc chimeric variants and
soluble hFcy-receptors were produced by transient transfection of 293T cells and
subsequent purification from culture supernatants. For protein production, cells were
cultured in DMEM medium supplemented with 1% Nutridoma SP (Roche). Cell culture
supernatants were harvested 6 days after transfection, and protein was precipitated by
ammonium sulfate precipitation. The 4m5.3-human Fc chimeric variants were produced
by transient transfection of 293F cells (Invitrogen) and subsequent purification from cell
culture supernatants. For protein production, cells were cultured in Freestyle 293F
Expression Medium (Invitrogen). Recombinant receptors were purified with Ni-NTA
(Qiagen) and recombinant antibodies were purified with protein G sepharose (GE
Healthcare) or immobilized protein A (Pierce) by affinity chromatography. All proteins
were dialyzed against PBS. Purity was assessed by SDS-PAGE followed by Coomassie
Blue staining.
Immune complex binding assay. For studying immune complex binding to surface
FcyRs, ICs were generated by incubating 10 gg of the respective 4m5.3 (anti-FITC)
chimera with 10 pg of BSA-FITC (Sigma) in 1 ml PBS for 2 hours at 37 *C while
shaking gently. CHO cells were stained for 2 hours at 4 'C with 1 pg, 0.5 gg, 0.2 gg or
0.1 gg of ICs, washed with PBS and analyzed by FACS analysis.
Surface Plasmon Resonance analysis. To determine the interaction between soluble
hFcy-receptors RIa (R&D Systems), RIIA 3 1H, RIIA13 1R, RIIB, RIIA, CIq (Calbiochem)
and 4m5.3 antibody chimera, steady state affinity measurements on a Biacore T100
biosensor were performed. Antibodies were immobilized at high densities to CM5 sensor
chips (Biacore) by standard amine coupling. Soluble hFcy-receptors were injected in 5
different concentrations through flow cells at room temperature in HBS-EP running
buffer (Biacore) for 3 min at a flow rate of 30 pl/min and dissociation was observed for
10 min. Kd values were calculated after subtraction of background binding to a control
flow cell using Biacore T100 Evaluation software.
Lectin blot. 10 pg of 4m5.3 wt, N297Q, and S298G/T299A antibody chimera were
resolved by SDS-PAGE using a polyacrylamide gel (NuPAGE, Invitrogen) under non-
reducing conditions. Proteins were transferred to a polyvinylidene difluoride (PVDF)
membrane (Millipore), blocked with Western Blocking Reagent (Roche), and followed
by incubation with biotinylated LCA lectin (2 gg/ml, Vector Laboratories) and alkaline
phosphatase-conjugated goat anti-biotin antibody (Sigma). Bound antibody was
visualized with 4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate
(Roche).
In vivo model systems. Mice were injected intravenously with 50 ptg 6A6-hFcl wt,
N297A, or S298G/T299A in 100 g1 PBS. Platelet counts were determined before
injection and at 4, 24, and 72 hours after injection by blood collection of 50 tl from the
retro-orbital plexus and measuring platelet counts of a 1:10 dilution in PBS/5% BSA in
an Advia 120 hematology system (Bayer). Platelet clearance for mice treated with each
6A6-hIgG1 variant was analyzed 4 h post-injection by a one-way ANOVA test using
SIGMASTAT. Error bars represent the standard deviation of three mice per group.
Computational modeling. Beginning from the crystal structure of the extracellular
portion of the FcyRIIIB receptor bound to the Fc region of the human IgG1
immunoglobulin (PDB ID lE4K) (7), structures were prepared using methods from
Lippow et al. (79). Hydrogen atoms were placed and the sidechains of HI 16(C) and
H131(C) on the receptor were flipped by 1800 around X2 and treated in their neutral, c-
protonated form. In the Fc fragment, all histidine sidechains were neutral and protonated
as indicated, to maximize hydrogen bonding potential: 268(A)-8, 268(B)-&, 285(A)-8,
285(B)-6, 310(A)-6, 310(B)-&, 429(A)-6, 429(B)-6, 433(A)-6, 433(B)-8, 435(A)-6, and
435(B)-6. A preliminary homology model of the corresponding FcyRIIA complex was
constructed on this backbone as follows. All non-alanine, non-glycine residues further
than 4.75 A from an interface residue were replaced by alanine. Both glycosylated and
aglycosylated forms of the structure were prepared, and in the glycosylated structure, a
sliding, restrained harmonic minimization was performed on the sidechain of the N-
glycosylated N297(B). Partial atomic charges for the N-glycosylated N297(C) residues
were derived by fitting to the electrostatic potential using the restrained fitting methods of
Bayly et al. (80) for each monosaccharide. The charges associated with hydrogens
missing in the polysaccharide were added to their parent atoms to ensure charge
conservation. To generate the FcyRIIA receptor structure, all FcyRIIIB interfacial
residues were mutated to their FcyRIIAR131 counterparts using the dead-end elimination
and A* protocol described by Lippow et al. (79) in the presence of wild-type or mutant
Fc region. For each mutant sequence, the global minimum energy conformation, as well
as a collection of progressively higher energy conformations, was identified in the
context of discrete rotameric conformational freedom of all placed sidechains except the
glycosylated form of N297. All of the Fc mutants examined were generated in the
presence of the receptor during this conformational search. Note that one interfacial
residue in the linker region of the FcyR structure (E86 in the FcyRIIA sequence) was left
as a glycine, as all glutamate rotamers searched had a van der Waals clash with the
receptor backbone. In the unbound FcyRIIA crystal structure (71), the two domains of
the receptor separate slightly to accommodate this larger residue. The solvent screened
electrostatic interactions and the residual electrostatic potential upon binding for these
structural models were computed by solving the linearized Poisson-Boltzmann equation
as described by Lee and Tidor (72). PARSE radii and charges were used for all
examined complexes (81).
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Figure 3.1
Cartoon representation of the crystal structure of the hIgG1 Fc complex with hFcyRIII (PDB ID
lE4K). FcyRI is shown in green, and both chains of the Fc in pale blue. Fc contact surfaces are
colored: lower hinge (orange), B/C loop (blue), C'/E loop (red), and F/G loop (purple). Fc
glycosylation is shown in yellow. The highlighted area shows an enlarged view of the C'/E loop
interaction with FcyRII. Fc residues 296-300 are shown as sticks.
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Full-length hIgG1 Fc display on the yeast cell surface. Yeast transformed with 4m5.3 heavy
chain and light chain secretion vectors are conjugated with NHS-PEG-fluorescein, then induced
for secretion in PEG-containing medium. IgG variants are preferentially captured on the
fluorescein-labeled yeast cell from which they were secreted (34). The displayed library is
subsequently screened with preformed tetramers consisting of biotinylated soluble hFcyRs and
fluorophore conjugated streptavidin (SA).
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Aglycosylated C'/E loop variants with FeyRIA binding.
(A) Unique sequences of aglycosylated Fc variants isolated for FcyRIIA binding after two rounds
of FACS. Displayed sequences represent the residues randomized in the saturation libraries,
positions 296-300, with the wild-type sequence underlined. Numbers in parentheses denote
number of times a particular mutant was isolated; in some cases, identical protein sequences were
isolated from multiple unique clones at the DNA level. Sequences of glycosylated variants
enriched from the screen have been omitted.
(B) Unique sequences of aglycosylated Fc variants isolated for FcyRIIA binding after a third
round of FACS, using a more stringent screening strategy.
(C) Binding of yeast-produced 4m5.3 hIgG1 variants to 10 nM FcyRIIA13 1R streptavidin-Alexa
647 tetramers. IgG from yeast culture supernatants was loaded onto fluorescein-conjugated yeast
and median fluorescence intensity (MFI) of receptor labeling was measured by flow cytometry.
Protein A Alexa 647 labeling of all samples was assessed to determine similar IgG loading (data
not shown). All data represent the average of two trials.
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S298G/ 0.3 7.0 1.7 5.7 n.b. n.b. n.b.
T299A
S298G/T299A binds to soluble and cell surface FcyRHA and FcyRIIB.
(A) Reducing SDS-PAGE of HEK-produced wild-type 4m5.3 hIgG1 and the aglycosylated
variants S298G/T299A and N297Q.
(B) Glycan blotting with the mannose-specific lectin LCA (upper panel). Coomassie staining of
SDS-PAGE was assessed to demonstrate similar protein loading (lower panel).
(C) Dissociation constants (Kd) for binding of FcyRs and Clq to wild-type 4m5.3 hIgG1 and
aglycosylated variants; n.b. indicates no binding detected.
(D) Labeling of CHO cell lines stably transfected with FcyRs with 4m5.3 IgG immune complexes.
Cells were incubated with 1 pg of ICs and analyzed by flow cytometry.
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C'I/E loop contacts with FcyRs. hFcyR family sequence alignment near predicted contacts with
the hIgG1 C'/E loop. Asn-Ser-Thr glycosylation motif shown in red. Position 131 of the aligned
FcyRs is shown in blue. Dotted lines represent predicted contacts between residues on the Fc and
FcyR (82).
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Platelet clearance in murine FcyR knockout, hFcyRIIA131R transgenic mice treated with chimeric
anti-platelet antibody 6A6 hIgG1 or the aglycosylated variants N297A and S298G/T299A. Mice(n=3) were injected with either antibody or PBS control and bled at 4, 24, and 72 h post-injection.
Normalized to platelet counts prior to injection, counts 4 h following injection of the 6A6
antibodies were 15.8 ± 13.9 % for wt, 39.5 ± 5% for S298G/T299A, 71.0 + 6.1% for N297A and
85.7 ± 11.0% for those treated with PBS only. S298G/T299A treated mice displayed a
statistically significant difference in platelet reduction compared to N297A (P = 0.017) and PBS(P = 0.002), but not a statistically significant difference compared to wt (P = 0.068).
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Homology model of wild-type and S298G/T299A Fc interactions with FcyRHA.(A) Structure of the wild-type B chain Fc fragment bound to the constructed FcyRIIA13 1R
homology model. The highlighted portion of the B chain shows the large N-glycosylated residue
making primarily intramolecular interactions. The portion of FcyRIIA (chain C) highlighted as
orange sticks shows those side chains that were conformationally relaxed, through rotamerization,
during model construction.
(B) Structure of the aglycosylated N297(B) interactions with a superposition of the possible
discrete side chain conformations (rotameric states) of N297(B), Ti 19(C), and S 126(C) in the
S298G/T299A mutant form of the Fc fragment.
(C,D) Structure of the Ki 17(C)-D265(B) salt bridge in the wild-type structure (panel C) enclosed
within the binding cavity in the presence of the oligosaccharide, and the same salt bridge as seen
in the aglycosylated S298G/T299A mutant (panel D).
(E,F) Residual potential after binding mapped onto the interaction face of the B chain of the Fc
fragment in the wild-type (panel E) and S298G/T299A mutant (panel F) structures. White regions
indicate areas of ideal complementarity between the Fc fragment and FcyRIIA13 1R, while deep red
or blue regions indicate areas of poor complementarity due to ligand desolvation costs
uncompensated by interactions made upon binding. Red corresponds to negative residual
potentials and blue to positive residual potentials. The coloring scale, identical in both panels, is
indicated in units of kT/e.
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(A-C) Yeast-secreted 4m5.3 hIgG1 point mutants were loaded on fluorescein-conjugated yeast
and assayed for binding to 10 nM FcyRIIA13 1R, FcyRlIIA76 , and FcyRIIIA176F streptavidin-
Alexa 647 tetramers by flow cytometry. All data represent the average of two trials and are
normalized to the wild-type signal; * indicates binding to variant not determined.
(D,E) Histograms of FcyRIIA131R streptavidin-Alexa 647 and FcyRIIIA 76V streptavidin-Alexa
647 tetramer labeling of weakly binding aglycosylated clones.
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Designed aglycosylated Fc mutants with FcyRiIA binding.
Yeast-secreted 4m5.3 hIgG1 C'/E loop double point mutants (A) or T299A point mutants with the
'second-site' mutations K326E and K290E/N (B) were loaded on fluorescein-conjugated yeast
and assayed for binding to 10 nM FcyRIIIAl' 6 , FcyRIIIA1 76F, and FcyRIIA131R (for panel A only)
streptavidin-Alexa 647 tetramers by flow cytometry. All data represent the average of two trials
and are normalized to the wild-type signal.
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Composition of the N-linked glycan attached to Asn297. GlcNAc, N-acetylglucosamine; Man,
mannose; Gal, galactose; Sial, sialic acid. Dark lines represent core glycosylation, dotted lines
represent glycoforns variably attached to the core structure.
Chapter 4. Engineering Aglycosylated Fc variants with FcyRIIIA
binding
Introduction
Over the past several decades, antibody-based therapy has emerged as a
promising mode of treatment of human disease, and in particular in the treatment of
human cancer (1, 2). While multiple mechanisms contribute to the efficacy of
therapeutic antibodies (1, 4), activation of immune effector functions has been shown to
play a critical role in the efficacy of several therapeutic antibodies, in particular through
an antibody's engagement of the Fcy receptors (FcyRs) of immune cells (5). Here, as in
immunity, IgGs act as the adaptor between a target cell or pathogen and the immune
response by simultaneously binding antigen through their variable regions and activating
an immune response through interaction of their conserved Fc regions with FcyRs on
immune cells.
The human FcyR (hFcyR) family consists of the activating receptors FcyRI,
FcyRIIA, and FcyRIIIA, and the inhibitory receptor FcyRIIB. While FcyRI binds IgG
with high affinity (nanomolar binding constants), FcyRIIA, FcyRIIB, and FcyRIIIA bind
IgG with micromolar affinity, becoming activated only via avid multivalent interactions
with opsonized antigen (60). In particular, the efficacy of therapeutic antibodies is
strongly correlated to the allelic forms of FcyRIIIA possessed by a given individual.
Populations homozygous for a valine at position 176 of FcyRIIIA (FcyRIIIA176 ), as
opposed to a phenylalanine (FcyRIIIA176F), have dramatically improved objective
response rates (13-16), likely due to a several-fold stronger binding of wild-type hIgG1
for the FcyRIIIA 176V allele.
Recently we demonstrated that aglycosylated human IgG1 Fc variants are capable
of engaging a subset of the low-affinity FcyRs with approximately wild-type binding
affinity and activating immune effector cells in vivo, demonstrating that N-linked
glycosylation of the Fc is not a strict requirement for FcyR engagement. Numerous
previous studies have shown that the binding of IgG to FcyR is highly sensitive to the
presence of a single N-linked glycosylation site at asparagine 297 (N297) of the Fc, with
deglycosylation resulting in a complete loss of FcyR binding (8, 21, 25, 62-64). Thus,
aglycosylated variants that maintain engagement to FeyRs have the potential to open up
therapeutic antibody production to virtually any expression system, removing the post-
translational variation in N-glycan synthesis that occurs across organisms, or in the case
of the common prokaryotic expression host E. coli, the complete absence of N-linked
glycosylation. Such variation in the nature of the N-linked glycan imparts substantial
changes in the affinity to FcyR and subsequent biological response (9, 10), and
additionally can lead to the presence of sugars that are rapidly cleared and/or
immunogemc.
Our initial screening methodology focused on engineering the Fc C'/E loop,
which contains the N-linked glycosylation site (Asn297-Ser 298-Thr299) as well as makes
direct contacts with FcyR (Figure 3.1). A library screen of all possible C'/E loop
variants yielded a variant (S298G/T299A) that binds FcyRIIA and FcyRIIB with
approximately wild-type affinity, but not FcyRIIIA. A second approach, based on
screening each single point mutation within the C'/E loop, then combining candidate
mutations, identified variants that weakly bind FcyRIIIA 17 6V - T299A, N297D, N297H,
and the double mutants N297D/S298T, N297D/S298A, and N297H/S298A -
demonstrating that aglycosylated Fcs can engage this FcyR as well. However, given the
importance of FcyRIIIA to therapeutic outcome, it is likely that these variants would have
limited therapeutic utility.
Building upon our previous work, we report here aglycosylated hIgG1 variants
that can engage all of the low-affinity hFcyRs with approximately wild-type or improved
binding affinity, thus identifying variants that might effectively substitute for the wild-
type, glycosylated hIgG1 . In doing so, we have focused on engineering additional loops
of the Fc domain that make contact with FcyR, screening libraries that encode all possible
amino acid diversity within segments of these loops to enrich variants with improved
FcyRIIIA176F binding. Such variants, when placed in the previously identified
aglycosylated backgrounds that allow for weak FcyRIIIA176v binding, yield fully FcyR
competent aglyco Fcs with a range of affinities. In addition, we find that our approach of
searching sequence space at contact loops in a focused manner, which allows us to
theoretically screen all possible amino acid diversity at these sites in short segments,
uncovered variants with mutations that act cooperatively, and thus not easily predicted by
combining the properties of single point mutations identifiable through other protein
engineering strategies.
Results
Engineering approach and screening methodology. Previously, we showed that the
binding affinity of aglycosylated Fcs can be modulated by placing 'second-site'
mutations selected for improved binding to FcyRs in a glycosylated background into an
aglycosylated background. Here, combining a mutation located near a contact interface
(K326E) with the mutation T299A improved FcyRIIIA binding relative to T299A alone,
while second-site mutations at a site distant from the contact interface (K290E/N) had no
effect upon aglycosylated Fc binding (Figure 3.9). This result suggested that modulating
the interactions about the Fc contact loops with FcyR, in a glycosylated background,
could likewise translate into improved binding affinity in an aglycosylated background.
To accomplish this, we set out to systematically ask which combinations of mutations at
Fc contact loops yield improved FcyRIIIA binding.
Here, we constructed saturation libraries about three contact sites within the Fc -
the lower hinge, the B/C loop, and F/G loop (Figure 4.1) - and screened them by
displaying these full-length hIgG1 variants on the surface of yeast. In this display system,
the femtomolar affinity scFv 4m5.3 (38) has been reformatted as a hIgG1, allowing 4m5.3
hIgG1 Fc library variants to be captured on fluorescein-labeled yeast from which they are
secreted (Figure 3.2) by adapting features of a cell surface secretion capture assay (34)
and the improved secretion of full-length hIgG1 from S. cerevisiae (Chapter 2). Contact
interface libraries were constructed by fully-randomizing four amino acid stretches using
degenerate NNK codons (N=ATCG, K=GT), which encode all 20 possible amino acids
in 32 codons. This design approach allows for over-sampling the codon diversity (324 ~
1x10 6), and thus amino acid diversity, in these yeast-based libraries, which often have a
transformation efficiency on the order of 1x10 7. The following libraries were constructed
and pooled by contact region: lower hinge (234-237, 236-239), B/C loop (265-268, 267-
270), and F/G loop (326-329, 327-330, 329-332, 331-334). As a target we chose the
FcyRIIIA176F allele, which, given its weaker binding for wild-type Fc, likely represents a
more stringent, as well as therapeutically relevant, barrier for improved FcyRIIIA binding.
Libraries were pooled by loop and individually screened by two rounds of enrichment on
FcyRIIIA176F coated magnetic beads followed by three rounds of fluorescence activated
cell sorting (FACS) at increasing stringency.
B/C and F/G loop variants enriched for improved FcyRIIIA binding. The sequences
of variants enriched for FcyRIIIA176F binding after the second and third rounds of FACS
(rounds four and five in total) for the B/C and F/G loop libraries are shown in Figure 4.2.
Enrichment of only wild-type clones was observed from the lower hinge libraries.
Clones enriched from the B/C loop libraries (Figures 4.2a,b) show an absolute
preference for D265, consistent with the importance of this residue in binding FcyR (21,
83). The majority of clones enriched from the screen have substitutions at positions 266-
268, indicating that variation within the 265-268 sublibrary more strongly contributed to
FcyRIIIA17 6F binding. Enriched variants show a strong preference for mutation of H268
to Glu, and to a lesser extent a likewise negatively charged Asp. At position 266 there is
a strong preference for either Leu or the wild-type Val, while position 267 appears to be
more promiscuous to substitution, with enrichment of the wild type Ser, as well as more
frequently Ala, Glu, and Asp. Of the clones enriched from the 267-270 sublibrary (i.e.
those clones with mutations at positions 269 and/or 270), there is a strong preference for
retaining negative charge at E269 and D270, either as the wild-type residue or as E269D
or D270E.
Clones enriched from the F/G loop libraries (Figures 4.2c,d) fall into two broad
classes of loop diversity - those enriched from the 326-329 sublibrary and those with
substitutions at the opposite end of the loop, primarily at position 332 and to a lesser
extent at 334, both of which have been previously identified as modulating FcyRIIIA
binding affinity (20-22). Substitution of 1332 with Glu dominates the screen, and has
been previously shown to greatly enhance binding to all FcyRs, including FcyRIIIA 176V
and FcyRIIIA176F (20). Virtually all clones potentially enriched from the 331-334
sublibrary (i.e. those with mutations at positions 333 and/or 334, or those lacking
mutations at positions 329 and 330 found in the 329-332 sublibrary) also contain a
substitution at position 334, with a preference for Val and Ala, and to a lesser extent Ser,
Glu, and Gln. These data are consistent with previous studies, in which K334A, K334E,
K334Q, and K334V were shown to strengthen binding FcyRIIIA (21), and the frequent
enrichment of K334E and K334N from a random mutagenesis library for improved
binding to FeyRIIIA (22).
Within the clones enriched from the 331-334 sublibrary there is a strong
preference for either the wild-type Pro at position 331 or Ser or Ala. P331A alone has
been shown to have no effect on FcyRIIIA176 v binding affinity, and P331S alone to
reduce FcyRIIIA176v binding (21). Interestingly, when P331 is mutated, it is almost
always derived from the 331-334 sublibrary and not the 329-332 sublibrary, suggesting
that the context of flanking residues is important to binding. Clones enriched from the
329-332 sublibrary have a strong preference for substitution at position 330, and thus
mutation of the wild-type Pro at position 331, within the background of 1332E and A330x
may be disfavored. Previous studies have shown that A330V alone slightly improves
FeyRIIIA176F binding (22) and A330L in the context of 1332E imparts improved
FceyRIIIA76
FcyRIIIA 1 76F binding (20).
In contrast, relatively little is known about how diversity at positions 326-328,
and in particular positions 327 and 328, impact FcyR binding. The variants enriched for
improved FcyRIIIA176F binding from our screen from the 326-329 sublibrary show a
strong preference for substitution of K326 with the hydrophobes Ile, Leu, and Val.
K326A has previously been shown to increase binding to all FcyRs (21), while K326E,
and to a lesser extent K3261 and K326Q, were frequently enriched in a screen for
improved binding to FcyRIIIA176V (22). In addition, multiple substitutions at position
326 impart improved binding to the complement component Clq (73). In our screen
A327 has a strong preference for Asp, although tolerates additional residues as well, with
the similarly negatively charged Glu, the wild-type Ala, and Gly appearing multiple
times; similarly, L328 has a strong preference for Ala and appears to tolerate multiple
substitutions, with Gly appearing multiple times. Within the clones enriched from this
sublibrary, P329 is absolutely conserved, consistent with its substitution being disfavored
within the 329-332 library. P329A alone has been shown to reduce binding to all FcyRs
(21).
Binding of HEK secreted B/C and F/G loop variants. To determine whether variants
enriched from this yeast-based screen impart improved FcyRIIIA binding when expressed
from a more standard host, a subset of variants were subeloned into mammalian
expression vectors, secreted from HEK 293 cells, and assayed for their relative ability to
16Fbind FcyRIIIA1 . Most B/C loop variants tested displayed a slight increase in binding
affinity to FcyRIIIA 176F compared to wild-type Fc (Figure 4.3a). Within the
S267A/H268E background, there is a slight preference Leu at position 266 compared to
the wild-type Val at position 266, suggesting that either of these residues can mediate
FcyRIIIA 176F binding. Within the V266L/H268E background, there is a slight preference
for Ala or Asp over the wild-type Ser at position 267, although substitution to Thr results
in a variant with reduced FcyRIIIA 176F binding. Interestingly, the addition of D270E in
the S267A/H268E background results in decreased binding to FcyRIIIA. The D270E
mutation alone has been shown to impart slightly improved binding to FcyIIIA but
weakened binding to FcyRIIA 3 1 R and FcyRIIB (21, 22) - FcyRs with Arg at position 131
of the receptor - suggesting that multiple mutations within this loop may not act in an
additive fashion.
Since the consensus mutations from our screen at positions 1332 and K334 have
been extensively characterized, we chose to look in more depth at the contributions of
positions 326, 327, and 328 of the Fc to FcyRIIIA binding (Figure 4.3b). As a whole,
these F/G loop variants bind FcyRIIIA 176F to a greater extent than the sampled B/C loop
variants, with two F/G loop variants, K3261/A327Y/L328G (IYG) and
K326I/A327E/L328E (IEA), binding FcyRIIIA 176F to a much greater extent than wild-
type Fc. Interestingly, the presence of a Tyr at position 327 in the K3261/L328G
background imparts a large increase in binding affinity, as K3261/L328G alone binds at
near wild-type levels.
To assess the contribution of the individual mutations within these clones, as well
as ask whether additional improved variants exist - such as those that could be present if,
for example 10-fold more clones were sequenced and analyzed - we performed a detailed
point mutant analysis of both the IYG and IEA variants (Figure 4.4). K3261 alone
imparts an increase in binding affinity to FcyRIIIA 176F, suggesting that part of the large
increase in binding affinity of the IYG and IEA variants compared to wild-type is due to
the presence of this mutation. Interestingly, no other combination of mutations other than
the triple mutant imparts improved binding in the IYG variant (and in most cases
dramatically weakens binding), suggesting that for this variant substitution at A327 and
L328, in the K3261 background, act cooperatively to impart improved receptor binding.
Similarly, substitutions at A327 and L328 in the IEA variant also act in a coordinated
way with K3261. L328A by itself weakens receptor binding, but when placed alongside
K3261 results in a double mutant with strengthened binding compared to K3261 alone.
Likewise, A327E alone and A327E/L328A weaken receptor binding, yet in the context of
the IEA variant yield substantially improved FcYRJIIA176F binding.
Binding of aglycosylated F/G loop variants. To assess whether enriched variants from
our screens could lead to aglycosylated Fcs with improved FcyRIIIA binding, the T299A
mutation was placed in the F/G loop variants described above, secreted from HEK cells,
and as a stringent test of binding affinity, assayed for their ability to bind FcyRIIIA176F
(Figure 4.5). Only T299A/K326I/A327Y/L328G (T299A/IYG) and
T299A/K326I/A327E/L328E (T299A/IEA) bound FcyRIIIA17 6 F with detectible affinity,
consistent with these mutations imparting the largest improvements in binding affinity in
the glycosylated background. In this assay, T299A/IYG binds FcyRIIIA176F to a slightly
greater degree than wild type hIgG1, and T299A/IEA to a slightly lesser degree. In
addition, both of these aglycosylated variants bind FcyRIIIA 176V, FcyRIIA13 1R, and
FcyRIIB at approximately wild-type or improved levels (Figure 4.6), demonstrating not
only that aglycosylated Fc variants can be engineered that bind FcyRIIIA, but that such
variants can be engineered to bind the panel of human low-affinity FcyRs as well. In
particular, the binding to FcyRIIB (Figure 4.6b) appears to be greatly strengthened
compared to wild-type Fc for the T299A/IYG and T299A/IEA variants, and given the
high sequence identity between receptors, likely greatly strengthened for FcyRIIA
(Figure 4.6a) as well (the similar signals in this panel likely represent saturation of
binding, as there is little reduction in signal with a 10-fold decrease in receptor labeling
concentration).
Modulating FeyRIIA and FcyRIIB binding of aglycosylated variants. Given the
large increase in binding to FcyRIIA and FcyRIIB imparted by using the T299A mutation
to place the F/G loop variants in an aglycosylated background, we next sought to reduce
the binding of the aglycosylated variant Fcs to these two receptors by placing the
K3261/A327Y/L328G (IYG) F/G loop variant in alternative aglycosylated C'/E loop
backgrounds. Previously, we identified the aglycosylated double mutants N297D/S298T
(DTT), N297D/S298A (DAT), and N297H/S298A (HAT), which weakly bind
FcyRIIIA176V, but have no detectible binding to FcyRIIA 13 1R (Figure 3.9a), suggesting
that these variants preferentially bind FcyRIIIA. The variants T299A/IYG, DTT/IYG,
DAT/IYG, and HAT/IYG all display varied FcyR-binding profiles (Figure 4.7), with the
DTT/IYG, DAT/IYG, and HAT/IYG variants having greatly reducing FcyRIIA and
FcyRIIB binding compared to T299A/IYG (Figures 4.7a,b), consistent with the binding
properties of T299A, DTT, DAT, and HAT alone. All variants appear to bind the
FcyRIIIA17 6V allele equally as well as wild-type Fc (Figure 4.7c), and most (DTT/IYG,
T299A/IYG, and DAT/IYG) display similar, if not slightly improved binding for the
FcyRIIIA176F allele (Figure 4.7d). Interestingly, HAT/IYG has greatly reduced binding
for both FcyRIIA and FcyRIIB, and is thus essentially FcyRIIIA specific. The DTT/IYG
and DAT/IYG variants come closest, in this assay, to displaying near wild-type binding
for all low affinity FcyRs - DAT/IYG has similar binding as wild-type Fc for FcyRIIA
and increased binding for FcyRIIB; DTT/IYG has reduced binding for FcyRIIA and
similar binding as wild-type for FcyRIIB. Taken together with the T299A/IYG variant,
these variants clearly demonstrate that aglycosylated IgG variants can be engineered to
bind all of the low-affinity FcyRs, and with a range of affinities and specificities.
Discussion
In the present study, we demonstrate that aglycosylated IgG variants can be
engineered to engage FcyRIIIA at wild-type or improved levels, and that these variants
can bind to all of the human low-affinity FcyRs. Such variants represent a further step
towards the development of fully-functional aglycosylated IgGs and the potential
production of therapeutic antibodies in virtually any expression system without regard to
post-translational processing.
In engineering these aglycosylated variants, we chose a modular design strategy,
based upon the hypothesis that properties imparted by altered contact loops will be
additive. In our previous work, we identified a series of C'/E loop mutations that impart
a range of aglycosylated FcyR binding properties. By combining these mutant
aglycosylated C'/E loops with an altered F/G loop isolated for improved FcyRIIIA 176F
binding, we have generated a series of aglycosylated Fc variants capable of binding
FcyRIIIA whose relative receptor binding properties mirror those of the C'/E loop
variants alone.
In addition, in screening for variants with improved FcyRIIIA binding, we chose a
directed evolution approach that allowed us to experimentally explore the sequence space
at the sites of Fc:FcyR interaction in a vastly more comprehensive manner than
previously reported approaches, which have included alanine scanning point mutagenesis
(21), screening random mutagenesis libraries of the entire Fc region (22), and in silico
prediction and experimental validation of variants (20). While it's likely that combining
previously described point mutations present in the literature would have also led to
variants with the properties we describe here, it was our hope that the approach we took
would allow us to add further insight to the current knowledge of Fc:FcyR interactions,
and in particular the engineering of these interactions.
The strength of this approach is highlighted in the variants enriched with
substitutions at positions 326-328. While many groups have identified substitutions at
position 326 that strengthen FcyR binding affinity (21, 22, 73), there has been no
demonstration that substitutions at positions 327 and 328 can also lead to improved
variants. In the context of the two best variants from our screen, IYG and IEA, our data
show that mutations at positions 327 and 328 are not additive, yet act in a cooperative
fashion to improve binding affinity. Such variants would not be found by combining
single point mutations identified for improved binding, and are extremely unlikely to be
found in screens of random mutagenesis libraries.
Our yeast display system allows for the rapid screening of millions of variants,
and for the most part enriches variants with properties that translate to improved binding
when secreted from mammalian cells. It is not without artifacts, however, and this is
particularly apparent in the clones enriched from the B/C loop libraries. While there is a
clear preference for several similar variants from these libraries, our screening assay
suggests that these variants as a whole do not substantially improve receptor binding.
This may reflect a limit to the degree to which this loop is capable of improving
FcyRIIIA binding (i.e. it has reached its near optimized level), and/or potentially reflect
variations in the affinity that these mutations impart in yeast-secreted antibodies
(containing yeast N-linked glycoforms) compared to HEK-secreted antibodies
(containing human glycosylation patterns).
Having shown that aglycosylated variants with these receptor binding properties
can be identified, it will be important to quantitatively describe their binding affinity to
the panel of human FcyRs, as well as test their activity in in vitro and in vivo models.
Murine models and clinical data suggest a strong correlation between therapeutic activity
and the presence of the low-affinity FcyRs (5) - FcyRIIA, FcyRIIB, FcyRIIIA - and thus
the variants described here may effectively substitute in these models for wild-type Fc. It
will also be important to assess the biophysical properties and serum half-life of these
IgGs, as previous work has shown reduced stability of deglycosylated wild-type hIgG1
(75) as well as the reduced stability of a glycosylated Fc variant engineered for improved
FcyR binding (74). Previous studies have shown that lack of glycosylation does not
affect serum half-life (25), and that most substitutions within these contact loops have
little effect upon FcRn binding (21).
Materials and Methods
Loop saturation mutagenesis library construction. Libraries were constructed by
homologous recombination of a mutated heavy chain constant region insert into the
4m5.3 heavy chain yeast secretion vector template according to previously published
methods (78). The 4m5.3 heavy chain secretion vector was previously constructed from
the pRS316 shuttle vector by insertion of the GALlO promoter and alpha terminator,
signal peptide, and 4m5.3 variable heavy chain domain upstream of the hIgG1 CHI to
CH3 constant domains (35). The 4m5.3 heavy chain template vector was prepared by
digestion with NheI (New England Biolabs) and XhoI (New England Biolabs), which
flank the hIgG1 constant domains.
Saturation mutagenesis of the lower hinge was performed by gene
reconstruction with the degenerate oligonucleotides 234-237NNK (all oligos from
Integrated DNA Technologies) and 236-239NNK; the B/C loop with 265-268NNK and
267-27ONNK; and the F/G loop with 326-329NNK, 327-33ONNK, 329-332NNK, and
331-334NNK (see Oligonucleotides below for sequences of all oligonucleotides used
during library construction). Degenerate oligos were designed as 52-mers, with 20 bases
of the wild type sequence flanking NNK codons (N=ATCG, K=GT) on both sides.
Briefly, in a first PCR step a template for incorporation of the degenerate oligo was
created by PCR amplifying the region directly 3' of the desired loop insertion site
through the 3' region of the CH3 domain, using the wild type vector as a template. For a
given library, this step used the forward primer ###-###flank-for (e.g. 265-268flank-for)
and the reverse primer 4m-CH3-epPCR-rev; ###-###flank-for is a 20-mer consisting of
the same 3' wild-type sequence in the degenerate oligo, which allows for incorporation of
the degenerate oligo in a second PCR step. In this second step, the gel purified PCR
product from step one was used as a template for the PCR incorporation and
amplification of the degenerate sequence, using the forward primer ###-###NNK (e.g.
265-268NNK) and the reverse primer 4m-CH3-epPCR-rev.
Gene assembly was performed by PCR extension of the above, gel purified
PCR product with a second PCR product, consisting of the 5' region of the gene with 20
bp of overlap with the 5' wild-type sequence of the degenerate oligo. This PCR product
was amplified from the wild-type vector using the forward primer 4m-CH1-epPCR-for
and the reverse oligo ###-###flank-rev (e.g. 265-268flank-rev); ###-###flank-rev is a 20-
mer consisting of the same 5' wild-type sequence in the degenerate oligo, allowing for
extension of the two PCR products to re-construct the entire CH1-CH3 regions. In a final
step, the gel purified extended PCR product was amplified with the oligos 4m-CH1-
epPCR-for and 4m-CH3-epPCR-rev, which amplify the 3' region of the 4m5.3 variable
heavy chain to the 3' end of the CH3 domain, reconstructing the heavy chain CHI to
CH3 gene insert with ~50 base pairs of overlap with the digested template vector for
efficient yeast homologous recombination.
Gene inserts were then transformed with digested template vector by
electroporation into the yeast strain YVH1O/LC, a derivative of the yeast strain YVH1O
(39), containing a chromosomally integrated copy of the 4m5.3 light chain yeast secretion
vector. All saturation libraries had approximately 1-2x10 7 transformants, 10- to 20-fold
greater than the theoretical diversity at the DNA level (324 ~ 1.Ox106).
Oligonucleotides.
4m-CH1-epPCR-for (5'-ATGGAATACTTGGGTCAAGGAACCTCAGTCACCGTCTCCGCTAGC)
4m-CH3-epPCR-rev (5'-ATTTTGTTACATCTACACTGTTGTTATCAGATTTCGCTCGAGTCA)
234-237NNK (5'-CACCGTGCCCAGCACCTGAANNKNNKNNKNNKCCGTCAGTCTTCCTCTTCCC)
236-239NNK (5'-GCCCAGCACCTGAACTCCTGNNKNNKNNKNNKGTCTTCCTCTTCCCCCCAAA)
234-237flank-for (5'-CCGTCAGTCTTCCTCTTCCC)
234-237flank-rev (5'-TTCAGGTGCTGGGCACGGTG)
236-239flank-for (5'-GTCTTCCTCTTCCCCCCAAA)
236-239flank-rev (5'-CAGGAGTTCAGGTGCTGGGC)
265-268NNK (5'-AGGTCACATGCGTGGTGGTGNNKNNKNNKNNKGAAGACCCTGAGGTCAAGTT)
267-270NNK (5'-CATGCGTGGTGGTGGACGTGNNKNNKNNKNNKCCTGAGGTCAAGTTCAACTG)
265-268flank-for (5'-GAAGACCCTGAGGTCAAGTT)
265-268flank-rev (5'-CACCACCACGCATGTGACCT)
267-270flank-for (5'-CCTGAGGTCAAGTTCAACTG)
267-270flank-rev (5'-CACGTCCACCACCACGCATG)
326-329NNK (5'-ACAAGTGCAAGGTCTCCAACNNKNNKNNKNNKGCCCCCATCGAGAAAACCAT)
327-33ONNK (5'-AGTGCAAGGTCTCCAACAAANNKNNKNNKNNKCCCATCGAGAAAACCATCTC)
329-332NNK (5'-AGGTCTCCAACAAAGCCCTCNNKNNKNNKNNKGAGAAAACCATCTCCAAAGC)
331-334NNK (5'-CCAACAAAGCCCTCCCAGCCNNKNNKNNKNNKACCATCTCCAAAGCCAAAGG)
326-329flank-for (5'-GCCCCCATCGAGAAAACCAT)
326-329flank-rev (5'-GTTGGAGACCTTGCACTTGT)
327-330flank-for (5'-CCCATCGAGAAAACCATCTC)
327-330flank-rev (5'-TTTGTTGGAGACCTTGCACT)
329-332flank-for (5'-GAGAAAACCATCTCCAAAGC)
329-332flank-rev (5'-GAGGGCTTTGTTGGAGACCT)
331-334flank-for (5'-ACCATCTCCAAAGCCAAAGG)
331-334flank-rev (5'-GGCTGGGAGGGCTTTGTTGG)
Library screening. Library screening was performed using the cell surface secretion
assay (CeSSA) (34). Briefly, pooled loop libraries were grown in SD-CAA (2% glucose,
0.67% yeast nitrogen base, 0.54% Na2HPO 4, 0.86% NaH2PO 4-H20, 0.5% casein amino
acids) to an OD 600 of - 5, and then induced in YPG (2% galactose, 2% peptone, 1% yeast
extract, 0.54% Na2HPO 4, 0.86% NaH2PO4-H20) for 12 hrs at 20 *C. Following this pre-
induction phase, yeast were labeled with fluorescein-PEG-NHS (Laysan Bio) and re-
induced in YPG containing 15% PEG (w/v) at 20 'C for 36 hrs. Cells were then washed
with PBS containing 0.1% (w/v) BSA (PBS/BSA).
For the first two rounds of screening, libraries were incubated with biotinylated
hFcyRIIIA176F preloaded onto streptavidin magnetic beads (Invitrogen), and enriched
variants captured by magnetic separation, with non-bound yeast discarded (Margaret
Ackerman, manuscript submitted). Beads were washed with PBS/BSA, then placed in
SD-CAA supplemented with penicillin/streptomycin (Invitrogen) to amplify captured
yeast cells. Starting with the third round of screening, yeast were labeled with
biotinylated hFcyRIIIA176F preloaded onto streptavidin-Alexa 647 (Invitrogen). The
subpopulations were sorted on either a BD FACSAria (Becton Dickinson) or a MoFlo
Cell Sorter (Cytomation Inc) and collected cells grown in SD-CAA supplemented with
penicillin/streptomycin (Invitrogen), for three additional rounds of screening (five rounds
in total). Library populations were labeled for FACS sorting at increasingly stringent
concentrations of FcyRIIIA176F tetramer as follows: round three (500 pM), round four (50
pM), and round five (50 pM).
Cloning and Site Directed Mutagenesis. Clones enriched from the yeast-based screen
were cloned from the yeast secretion vectors into the gWIZ mammalian expression vector
(Genlantis) by a variation of the Quikchange mutagenesis protocol (84). Fc domains
were PCR amplified from the pRS316 based heavy chain yeast secretion vector with the
oligos:
gWIZ-Fc-for = (5'-GAGCCCAAATCTTGTGACAA)
gWIZ-SalI-rev = (5'-TCACACGTGTCGACTTATCATTTACCCGGAGACAGGGAGA)
which allow for > 20 bp of homology to the wild-type segment in the gWIZ vector. PCR
products were gel purified and used as oligos for PCR-amplification of the entire variant
vector, incorporating the sequence of the Fc variant.
Point mutants were constructed by PCR-amplification of the entire vector using
complementary primers containing the desired point mutations.
Characterization of HEK-secreted Fc mutants. Unless otherwise noted, Fc variants
were transiently transfected into HEK 293F cells (Invitrogen) in a 6-well plate format.
Cell culture supernatants were loaded onto fluorescein-conjugated yeast overnight at
4 'C; yeast were then washed with PBS/BSA, labeled with biotinylated FcyR preloaded
onto streptavidin-Alexa 647 at 4 'C for > 2 hrs, and analyzed by flow cytometry.
Labeling with 10 pg/ml Protein A-Alexa 647 (Invitrogen) was performed as a separate
IgG loading control for all samples. FcyR labeling fluorescence for individual variants
was normalized by the surface IgG loading of a variant relative to that of wild-type IgG,
as determined by relative Protein A-Alexa 647 labeling. There was strong agreement
(within 10% difference) between this approach to signal normalization and gating on a
population of cells to give similar surface loading signals.
Antibodies and recombinant proteins. The 4m5.3-human Fc chimeric variants were
produced by transient transfection of 293F cells (Invitrogen) and subsequent purification
from cell culture supematants. For protein production, cells were cultured in Freestyle
293F Expression Medium (Invitrogen). Recombinant antibodies were purified with
immobilized protein A (Pierce) by affinity chromatography. All proteins were dialyzed
against PBS. Purity was assessed by SDS-PAGE followed by Coomassie Blue staining.
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Fc:FcyR contact interfaces. (A) Cartoon representation of the crystal structure of the hIgG1 Fc
complex with hFcyRIII (PDB ID: 1E4K). FcyRIII is shown in green, and both chains of the Fc in
pale blue. Fc contact surfaces are colored: lower hinge (orange), B/C loop (blue), C'/E loop (red),
and F/G loop (purple). Fc glycosylation is shown in yellow. (B) Residues randomized in the Fc
loop libraries used in the screen. Dark black bars represent four amino acid stretches that were
completely randomized.
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Sequences of B/C and F/G loop variants enriched from the FcyR IA1 7 6F binding screen.
Sequences of B/C loop clones enriched after the fourth (A) and fifth (B) rounds of screening.
Sequences of F/G loop clones enriched after the fourth (C) and fifth (D) rounds of screening.
Dashes represent the same residue as the wild-type sequence. Numbers in parentheses represent
the number of times a particular clone was present in the population sequenced.
82
Figure 4.3
o+=
265 D
V
9
H
E
270 D
N297Q - - ---- 326 K N297Q L V I I I I
L L L L - - - A 
- D E D - Y
- E A TA A A 328 L A A A T G GE E E E E E E
D - (WT)
E
(WT)
Relative binding of clones enriched from screen. B/C loop (A) and F/G loop (B) 4m5.3 Fc
variants enriched for improved FcyRIIIA17 6F binding from the yeast-based screen were expressed
from HEK cells and assayed for relative binding to FcyRJIIA17 6F compared to wild-type (WT).
Fluorescein-labeled yeast were incubated with cell culture supernatants, then labeled with either
0.5 nM or 5.0 nM of streptavidin Alexa 647 FcyR tetramer, and then cells analyzed by flow
cytometry. Data represent the average of two trials, normalized by the relative IgG surface
loading of a given variant compared to wild-type, as determined by a separate Protein A 647
loading control. Dashes represent the same residue as the wild-type sequence.
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Mutational analysis of IYG and IEA variants. 4m5.3 Fc variants, comprising the ensemble of
mutations present in the K3261/A327Y/L328G (1YG) and K3261/A327E/L328A (IEA) variants
were assayed for binding to FcyRIIIA176F. Fluorescein-labeled yeast were incubated with cell
culture supernatants, labeled with 5 nM of streptavidin Alexa 647 FcyR tetramer, and then cells
analyzed by flow cytometry. Data represent the average of two trials, normalized by the relative
IgG surface loading of a given variant compared to wild-type (WT), as determined by a separate
Protein A 647 loading control. Dashes represent the same residue as the wild-type sequence.
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FcyRIIA binding of aglycosylated F/G loop variants. Aglycosylated variants of the F/G loop
clones enriched for improved FcyRIJA17 6F binding, described in Figure 4.3, as well as the most
frequently enriched B/C loop clone (V266L/S267E/H268E), were assayed for binding to
FcyRIIA176F. The T299A mutation, which confers weak aglycosylated binding to FcyRIIIA 76V,
was introduced into all clones. Fluorescein-labeled yeast were incubated with cell culture
supernatants, labeled with either 0.5 nM or 5.0 nM of streptavidin Alexa 647 FcyR tetramer, and
then cells analyzed by flow cytometry. Data represent the average of two trials, normalized by
the relative IgG surface loading of a given variant compared to wild-type, as determined by a
separate Protein A 647 loading control. Dashes represent the same residue as the wild-type
sequence.
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FeyR binding of T299A/IEA and T299A/IYG variants. T299A/IEA and T299A/IYG were
assayed for relative binding to the panel of human FcyRs: (A) FcyRIIA13 1R, (B) FcyRIIB, (C)
FcyRIIAl 76V, and (D) FcyRIIIA176 F. Fluorescein-labeled yeast were incubated with cell culture
supernatants, labeled with either 0.5 nM or 5.0 nM of streptavidin Alexa 647 FcyR tetramer, and
then cells analyzed by flow cytometry. Data represent the average of two trials, normalized by
the relative IgG surface loading of a given variant compared to wild-type, as determined by a
separate Protein A 647 loading control.
Figure 4.6
1-
1000-
10-
1000-
T299N
IYG
T299N
IYG
g0.5 nm
S5.0 nM
Figure 4.7 (a, b)
IIA
1200-
1000-
800-
800-
400-
200-
299AflYG
-- a
-U- --
a- --
DTTIIYG
0.01 0.1 1 11
1200.
1000-
HAT/IYG
IIB 299AlYG
1-
--
U-
DAT/IYG
WT
FcR tetramer (nM)
B
.
4.0
cm
I
Figure 4.7 (c, d)
C lilA'76v
1200-
m- 
-V- - HA T
%N 00
E . 10
DS lilA176FG
-4 - DTT/lYG
4009A DATYYG
A/ HAT/YYG
200
2WWT
0.01 0.1 1 10
D IIIAI76F
5M0
2 (* DTTIIYG
t'U299A/YG
Z300 -
iDATIIYG
E 200
WT
00 sno HATIIYG
0 as as
0.01 0.1 1 10
FcR tetramer (nM)
Fc'yR binding of aglycosylated lYG variants. T299A/K32611A327Y/L328G (T299AIIYG),
N297D/S298T/K32611A327Y/L328G (DTT/IYG), N297D/S298A1K3261!A327Y/L328G
(DAT/IYG), and N297H/S298A/K3261/A327Y/L328G (HAT/IYG) were assayed for relative
binding to the panel of human FcyRs: (A) FcyRIIA13 1R, (B) FcyRIIB, (C) FcyRIIAl' , and (D)
FcyRIIIA176 F. Fluorescein-labeled yeast were incubated with 20 pg/ml purified IgG, labeled with
streptavidin Alexa 647 FcyR tetramers at a range of concentrations, and then cells analyzed by
flow cytometry. Data represent the average of two trials; MFI = median fluorescence intensity.
Similar IgG surface loading of a given variant compared to wild-type was confirmed by a
separate Protein A 647 loading control.
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Chapter 5. Engineering Fc variants with specificity for FcyRIIIA
Introduction
The activation of immune effector functions, in particular through the engagement
of cellular Fcy receptors (FcyRs), is a critical mechanism in the efficacy of several
therapeutic antibodies (5). In immunity, antibodies act as a bridge between a pathogen
and immune effector cells, simultaneously binding antigen through their variable regions,
while activating immune cells through interaction of their conserved Fc domains with the
FeyRs of immune cells. This process, termed antibody-dependent cellular cytotoxicity
(ADCC), leads to phagocytosis of the bound pathogen and release of inflammatory
mediators (5), and in therapeutic antibodies directed against tumor-specific antigens, can
lead to immune cell mediated killing of antibody-bound tumor cells.
The human FeyR (hFcyR) family consists of the activating receptors FeyRI,
FeyRIIA, and FeyRIIIA, and the inhibitory receptor FeyRIIB. While FeyRI binds IgG
with high affinity (nanomolar binding constants), FcyRIIA, FeyRIIB, and FcyRIIIA bind
IgG with micromolar affinity, becoming activated only via avid multivalent interactions
with opsonized antigen. Several studies point to the importance of the low affinity FeyRs
in therapeutic efficacy (5) and have suggested ways in which modulating the properties
of the IgG Fe and its interaction with FeyR may enhance therapeutic response (17).
Enhanced ADCC has been observed in mice lacking the lone inhibitory receptor
FeyRIIB (11), and additional murine models suggest that the ratio of the binding affinity
of a therapeutic IgG for an activating receptor compared to that of the inhibitory receptor
(the activating to inhibitory, or A/I ratio) is predictive of therapeutic outcome (12). Other
studies, including clinical data, point to the importance of allelic variation within human
FeyRIIIA in therapeutic outcome (13-16). Populations homozygous for a valine at
position 176 of FeyRIIIA (FeyRIIIA 176V), as opposed to a phenylalanine (FcyRIIIA176F),
have dramatically improved response rates, likely due to a several-fold stronger binding
affinity of wild-type hIgG1 for the FcyRIIIA17 6V allele.
Such observations have led to the development of Fe variants with improved, and
more specific binding to FcyRIIIA, either through engineering the glycan attached to
asparagine 297 (N297) of the Fc (9, 18, 19, 85), or through modifying the characteristics
of the Fc polypeptide itself (20-22). The three most well characterized polypeptide
variants, S239D/A330L/1332E (20), F243L/R292P/Y300L/V305I/P396L (22), and
S298A/E333A/K334A (21), achieve improved FeyRIIIA binding with a range of
FcyRIIB affinities. S239D/A330L/1332E confers an ~ 100-fold increase in FcyRIIIA
binding as well as increased FcyRIIB binding; F243L/R292P/Y300L/V305I/P396L has
an ~ 10-fold increase in FcyRIIIA binding and approximately wild-type FcyRIIB binding;
and S298A/E333A/K334A has increased binding affinity for FcyRIIIA and dramatically
reduced affinity for FcyRIIB. These Fc variants have been shown to have dramatically
enhanced ADCC in in vitro models, as well as reduced tumor progression in xenograft
models. Interestingly, a recent study using cell based assays showed a correlation
between immune cell activation and binding affinity to activating receptors, but little
correlation with FcyRIIB binding (23), raising the question of whether enhanced
therapeutic outcome can be achieved by optimizing the activating receptor binding
properties alone, or whether binding to the inhibitory receptor, FcyRIIB, also plays a role
in therapeutic outcome.
In the present study, we have sought to, in a comprehensive manner, expand the
window of specificity for the activating FcyRIIIA over the inhibitory FcyRIIB that can be
engineered into the human IgG1 Fc domain. Here, we have focused on screening for
variants with enhanced FcyRIIIA17 6F binding but dramatically reduced FcyRIIB binding,
simultaneously improving binding to the less-responsive low-affinity FcyRIIIA allele
population while eliminating or reducing the inhibitory component to immune cell
activation. We describe a screen that samples amino acid diversity at the loops of the Fc
that make contact with FcyR, asking what combinations of mutations at these sites impart
specificity in an experimentally much more comprehensive manner than previously
reported. Our screen returns previously identified mutations within these loops that
impart specificity, as well as additional mutations flanking these residues, not previously
reported, that enhance specificity.
Results
Engineering approach and screening methodology. Recently, our group developed
and characterized a method for the improved enrichment (or depletion) of extremely
weak binding proteins from yeast-display libraries using the avidity enhancement of
antigen-coated magnetic beads (Margaret Ackerman, manuscript submitted). Depletion
of binders from yeast-display libraries can be efficiently accomplished through
successive rounds of incubation of libraries with target antigen-coated beads without
library re-amplification, increasing the likelihood of eliminating binders from the
population with each pass. This methodology is similar to the one described by
Stavenhagen and coworkers to engineer Fc specificity with yeast display libraries (22),
but as discussed later, has some key differences that likely improve specificity screening.
To screen for receptor specificity, we set out to systematically ask what
combinations of mutations at Fc contact loops yield FcyRIIIA-specific binding,
experimentally exploring the sequence space at these interaction sites in a vastly more
comprehensive manner than previous approaches, which have included alanine scanning
point mutagenesis (21), screening random mutagenesis libraries of the entire Fc region
(22), and in silico prediction and validation of variants (20). While mutations distant
from Fc:FcyR contact interfaces have been shown to impart specificity (21, 22), likely
through conformational changes in the Fc, we reasoned that focusing on sampling amino
acid diversity within the loops of the Fc in direct contact with FcyRs would have the
greatest impact on specificity.
Here, we constructed saturation libraries about three contact sites within the Fc -
the lower hinge, the B/C loop, and F/G loop (Figure 4.1) - and screened them by
displaying these full-length hIgG1 variants on the surface of yeast. In this display system,
the femtomolar affinity scFv 4m5.3 (38) has been reformatted as a hIgG1, allowing 4m5.3
hIgGi Fc library variants to be captured on fluorescein-labeled yeast from which they are
secreted (Figure 3.2) by adapting features of a cell surface secretion capture assay (34)
and the improved secretion of full-length hIgG1 from S. cerevisiae (Chapter 2). Contact
interface libraries were constructed by fully-randomizing four amino acid stretches using
degenerate NNK codons (N=ATCG, K=GT), which encode all 20 possible amino acids
in 32 codons. This design approach allows for over-sampling the codon diversity (32 4 ~
1x10 6), and thus amino acid diversity, in these yeast-based libraries, which often have a
transformation efficiency on the order of 1x10 7. The following libraries were constructed
and pooled by contact region: lower hinge (234-237, 236-239), B/C loop (265-268, 267-
270), and F/G loop (326-329, 327-330, 329-332, 331-334).
Yeast capture libraries were depleted multiple times in succession on FcyRIIB
coated magnetic beads, then screened for binding to the FcyRIIIA176F allele, initially on
receptor-coated magnetic beads, and during later rounds of screening, at increasing
stringency by fluorescent activated cell sorting (FACS). Given its weaker binding for
wild-type Fc, FcyRIIIA176F likely represents a more stringent, as well as therapeutically
relevant, barrier for improved FcyRIIIA binding.
Variants enriched for FcyRIIIA176F specific binding. All variants enriched for
FcyRIIIA specific binding from the B/C loop libraries originated from the 267-270
sublibrary, suggesting that this region of the loop dominates specificity (Figure 5.1a,b).
Among the clones isolated, there is an absolute preference for substitution at D270,
predominately to Glu, consistent with previous studies that have shown that the D270E
variant slightly strengthens binding to FcyRIIIA176F while reducing binding to FcyRIIB
(21, 22). In addition, H268 is altered in virtually all clones, with a slight preference for
the acidic residues Asp and Glu, although multiple substitutions are present, with Met
and Thr also occurring at this position multiple times. The most abundant residue present
at position 269 is Asp, with the similarly negatively charged wild-type Glu also appearing
multiple times. Position 267 displays the least variation among the clones enriched from
the screen, with a strong preference for the wild-type Ser, or in some variants, Asp.
Similarly, all variants enriched for FcyRIIIA-specific binding from the pooled
F/G loop libraries are derived from the 329-332 sublibrary, suggesting that this region of
the loop dominates specificity (Figure 5.1c,d). Enriched variants display a strong
consensus motif, containing P329A, A330L/V/I/E, and 1332E/D, with a strong preference
for 1332E. 1332E alone has been shown to increase binding to all FcyRs (20), and A330L,
when placed in the S239D/1332E background, improves receptor specificity, slightly
strengthening FcyRIIIA binding while weakening FcyRIIB binding (20). A330V alone
has been shown to confer FcyRIIIA-specific binding (22); P329A alone greatly reduces
binding to all FcyRs (21).
Characterization of FcyRIHIA176F-specific loop variants. To characterize the variants
enriched from our yeast-based screen, we cloned pools of clones into mammalian
expression vectors, sequenced to confirm clone identity, and expressed individual IgG
variants from HEK 293 cells. Cell culture supernatants were loaded onto fluorescein-
labeled yeast, then variants analyzed for their ability to bind fluorescently labeled FcyR-
streptavidin tetramers, and data normalized by relative surface IgG loading. All variants
analyzed in this assay display substantial improvements in FcyRIIIA 176F binding
specificity, although the degree of specificity varies across the clones analyzed (Figure
5.2). The F/G loop variants, all highly similar in sequence, have dramatic increases in
FcyRIIIA176F binding and large reductions in FcyRIIB binding, with one clone,
P329A/A330E/1332E (AE*E) displaying undetectable FcyRIIB binding at the
concentration of receptor used in the screening assay (Figure 5.2b). Scanning across the
F/G loop variants, it appears that the presence of Glu at 332 as opposed to Asp imparts
improved FcyRIIIA17 6 F binding in the P329A/A330L background, and that the
hydrophobic residues Leu and Val impart similar binding properties in the P329A/1332E
background, while an Ile at this position reduces binding affinity.
Substantial variation, in both sequence and binding properties, exists in the B/C
loop clones analyzed (Figure 5.2a). A subset of clones achieve specificity by virtually
eliminating (at the concentration tested) FcyRIIB binding, while maintaining
FcyRIIIA 176F binding at near wild-type, or even reduced, levels. Another subset reduces,
although does not ablate, FcyRIIB binding, yet realizes improvements in specificity
through additional increases in FcyRIIIA176F binding. Among the clones analyzed, some
observations can be made about the role of individual mutations within the context of
other mutations within a variant. Within the S267D/D270S background, the presence of
Asp at position 267, as compared to Met, substantially increases binding to both FcyRs;
similarly, within the H268E/E269D background, the presence of a Glu at position 268, as
opposed to Met, also substantially increases binding to both FcyRs. Within the
H268E/E269D background, the presence of Glu at position 270, as opposed to Gln,
imparts increased binding affinity to both receptors. Finally, within the H268T/D270E
background, an Asp at position 269, as opposed to the wild-type Glu, allows for greatly
improved FcyRIIIA176F binding without a detectible increase in FcyRIIB binding.
Effect of P329A in F/G loop clones. To understand the contribution of individual
mutations from the most interesting variants identified from our screen, we constructed
point mutants and assayed them for receptor binding. The F/G loop variant A330L/1332E
has been previously identified and characterized, as part of a triple mutant
S239D/A330L/1332E, and we sought to understand the contribution of the P329A
mutation that was universally enriched from our screen (Figures 5.1c,d). Compared to
A330L/1332E, P329A/A330L/1332E appears to yield a slight decrease in FcyRIIIA176F
binding, yet weakens FcyRIIB binding to a greater extent (Figure 5.3). Similar to the
results from the initial screen using cell culture supernatants (Figure 5.2b), the presence
of Glu at position 330 in the variant P329A/A330E/1332E, compared to Leu in
P329A/A330L/1332E, significantly weakens binding to all FcyRs, yielding a variant with
virtually no FcyRIIB and FcyRIIA binding, and strengthened (compared to wild-type Fc)
binding to FcyRIIIA176F. The F/G loop only variants have weakened binding to all FcyRs
compared to the previously described S239D/A330L/1332E. In this assay, the S239D
mutation, in the context of A330L/1332E, strengthens binding to all FcyRs, albeit appears
to enhance binding to FcyRIIB and FcyRIIA131R to a greater extent than to FcyRIIIA176F
Overall, the variant enriched from the screen, P329A/A330L/1332E, appears to have
weakened FcyRIIIA17 6 F binding compared to S239D/A330L/1332E, yet dramatically
reduced FcyRIIB binding.
Mutational analysis of the B/C loop clone H268T/E269D/D270E. To understand the
contribution of individual mutations in the triple mutant H268T/E269D/D270E (TDE),
the most promising B/C loop variant from the initial screen (Figure 5.2a), we compared
the relative receptor binding of the previously identified variant D270E, which has been
shown to confer FcyRIIIA specific binding, to H268T/E269D/D270E and the double
mutants H268T/D270E and E269D/D270E (Figure 5.3). Similar to previous reports,
D270E alone slightly increases FcyRIIIA17 6F binding while greatly reduces FcyRIIB
binding. Placing H268T in the D270E background reduces binding to FeyRIIIA176F
similar to that of wild-type Fc, which is consistent with the data from the initial screen
using cell culture supernatants (Figure 5.2a). In contrast, placing E269D in the D270E
background results in a double mutant with strengthened FcyRIIIA176F binding compared
to D270E alone, and with similar, barely detectible binding to FcyRIIB. E269D/D270E
binds FcyRIIIA176F to a greater extent than H268T/E269D/D270E, further suggesting that
H268T has a deleterious effect on receptor binding. Interestingly, E269D/D270E was
among the myriad clones enriched from the yeast-based screen (Figure 5.1a), suggesting
that further screening of HEK-expressed variants from the enriched population would
have uncovered this variant, as well as potentially additional variants with desirable FcyR
binding properties.
Effect of loop grafting on receptor binding properties. Since the initial library screen
for receptor specificity only looked at Fc variants with diversity in four amino acid
stretches, which were confined to individual loops at the Fc:FcyR contact interface, we
sought to improve the properties of the variant Fcs by grafting B/C and F/G loops from
enriched variants into a single Fc (Figure 5.4). We reasoned that since the Fc
homodimer binds the monomeric FcyR asymmetrically (6, 7) - with the F/G loop from
one chain of the Fc making extensive contacts with FcyR and the B/C loop from the other
chain of the Fc making extensive contacts - the binding properties of such loop grafted
variants would be additive. Both H268T/E269D/D270E/P329A/A330L/1332E
(TDE/AL*E) and H268T/E269D/D270E/P329A/A330E/I332E (TDE/AE*E) have
slightly strengthened binding to FcyRIIIA 176F compared to the F/G loop only variants
P329A/A330L/1332E (AL*E) and P329A/A330E/1332E (AE*E), consistent with the B/C
loop variant H268T/E269D/D270E (TDE) imparting slightly improved binding to
FcyRIIIA176F compared to wild-type Fc (Figure 5.4a). Interestingly, the presence of the
mutant B/C loop dramatically reduces binding to FcyRIIB (Figure 5.4b), as TDE/AE*E
appears to have completely ablated FcyRIIB binding and TDE/AL*E substantially
reduced FcyRIIB binding.
Comparison of engineered variants to published variants. As a final test of our
engineering approach, we sought to compare the B/C and F/G loop-grafted variants to the
previously reported variants mentioned above: S298A/E333A/K334A, engineered by a
group at Genentech using alanine scanning mutagenesis (21); S239D/A330L/1332E,
engineered by a group at Xencor using in silico prediction and screening (20); and
F243L/R292P/Y300L/V3051/P396L, engineered by a group at Macrogenics using yeast
display libraries of randomly mutated Fc domains (22). These variants display a range of
affinities and specificities in our assay (Figure 5.5), and the relative data correlate well
with previously reported affinities and specificities (20-22): S298A/E333A/K334A has
been reported to increase binding affinity to FcyRIIIA176F while nearly abrogating
binding to FcyRIIB; S239D/A330L/1332E to greatly enhance binding to both receptors;
and F243L/R292P/Y300L/V3051/P396L to greatly strengthen binding affinity to
FcyRIIIA 176F while maintaining FcyRIIB binding at near wild-type levels.
As a comparison, we chose the loop grafted variants TDE/AL*E and TDE/AE*E,
as well as the variants, E269D/D270E/P329A/A330L/1332E (*DE/AL*E) and
E269D/D270E/P329A/A330E/1332E (*DE/AE*E), in which position 268 is maintained
as the wild type His, motivated by the slight improvement in FcyRIIIA176F binding for
E269D/D270E compared to H268T/E269D/D270E (Figure 5.3a). The pairs TDE/AL*E
and *DE/AL*E, and TDE/AE*E and *DE/AE*E, display similar binding curves to all
receptors (Figure 5.5), suggesting that the H268T mutation - in the context of the loop
grafted variants - has little effect on receptor binding properties. The properties of the
loop grafted variants are most similar to S298A/E333A/K334A, achieving strengthened
FcyRIIIA176F binding with similar, near abrogated FcyRIIB binding (Figures 5.5, 5.6).
TDE/AL*E and *DE/AL*E appear to bind FcyRIIIA176F at levels intermediate that of
F243L/R292P/Y300L/V3051/P396L and S239D/A330L/1332E, suggesting an
approximately 10-fold to 100-fold improvement in binding affinity to this allele; 10-fold
and 100-fold enhancements have been previously measured for these variants by SPR (20,
22). Variants with a Glu at position 330 (TDE/AE*E and *DE/AE*E) have smaller
increases in FcyRIIIA 176F binding - similar, if not strengthened compared to
S298A/E333A/K334A - with undetectable binding to FcyRIIB in this assay.
Discussion
Previous approaches to engineering improved binding affinity and specificity
within the IgG Fc domain for FcyR have varied widely in their methodology, throughput,
and exploration of Fc sequence space. In an initial analysis to understand the
contribution of individual Fc positions to receptor binding, Shields and coworkers
constructed a comprehensive set of surface exposed alanine point mutants within the
human IgGi Fc and individually assayed each variant for relative FcyR binding, then
combined mutations identified by their alanine scanning mutagenesis to construct
variants with enhanced properties (21). More recently, Lazar and coworkers used
computational modeling of Fc:FcyR interactions to screen variants in silico, then
experimentally validate candidate mutations, individually and in combination (20). Also
more recently, Stavenhagen and coworkers used a directed evolution approach, screening
randomly mutated yeast-display Fc libraries for improved binding to FcyRIIIA, as well as
for loss of FcyRIIB binding followed by enrichment for FcyRIIIA binding (22), then
similarly analyzed consensus mutations from enriched clones, individually and in
combination, to generate variants with defined properties.
The approach we describe here is similar to the one employed by Stavenhagen et
al, yet with modifications in display system design, and importantly, in library
construction and screening methodology. Similar to Stavenhagen et al, we chose to use a
directed evolution approach to experimentally screen large collections of variants, taking
advantage of the eukaryotic protein processing of S. cerevisiae to display Fc variants on
the surface of yeast. In our system, we have chosen to present the Fc in the context of the
fully-assembled human IgGi using a cell surface secretion capture assay (34). In addition,
we chose to build upon this approach by: 1) focusing on better sampling the sequence
space about the Fc:FcyR contact loops, which we would predict would have the largest
impact upon binding specificity, and before this study had not been comprehensively
addressed, and 2) employing an improved methodology for screening for binding
specificity from yeast-displayed libraries, based upon recent work from our group
(Margaret Ackerman, manuscript submitted).
While sites distant from the contact interface have been shown to have effects
upon binding affinity and specificity (21, 22), we hypothesized that a large component of
the binding properties of the Fc domains could be modulated by focusing directly on the
loops of the Fc that make contact with FcyR. While variants within these loops have
been previously identified through all of the approaches outlined above, we hypothesized
that we could uncover additional mutations missed by these previous screening
approaches by a more thorough examination of sequence space, completely sampling all
combinations of mutations within these loops in four amino acid stretches.
We also use a stringent screening approach for finding variants with dramatic
losses in binding to the inhibitory FcyR, FcyRIIB. As in (22), we use the avidity
enhancement of magnetic beads to remove FcyRIIB-binding clones from the library, yet
rather than re-amplifying the library before performing positive enrichment for FcyRIIIA
binding clones in a second round of screening, we subject the depleted population to
additional rounds of depletion on FcyRIIB-coated magnetic beads, then an ultimate
positive selection for FcyRIIIA binding, before re-amplifying the sublibrary. Our data
have shown absorption of yeast-displayed binding clones in a model system on magnetic
beads to be approximately 80% efficient, with successive rounds of depletion before re-
amplification pushing the efficiency of absorbing binding clones to > 95%.
The variants enriched from our screen from both the B/C loop and F/G loop
libraries are similar to those previously identified, although contain elements that allow
for enhanced receptor specificity, in particular through reduced FcyRIIB binding,
consistent with our screening approach. In particular, all of the clones enriched from the
B/C loop libraries contain substitutions as D270, which has previously been identified as
modulating FcyR specificity (21, 22). Our approach reveals a flanking mutation, E269D,
that when placed in the D270E background, enhances FcyRIIIA17 6F binding while
maintaining greatly reduced FcyRIIB binding. Within the F/G loop, there is a clear
consensus for variants with substitutions at positions 330 and 332 (to Glu), a background
that has been previously identified by in silico screening (20). Our screen also results in
an absolute preference for variants with the flanking mutation P329A, which reduces
FcyRIIB binding, with a slight decrease in FcyRIIIA 176F binding. In addition, our
approach also identifies variants with diversity at position 330, in particular
P329A/A330E/1332E, which, while improving FcyRIIIA176 F binding, has undetectable
FcyRIIB binding.
Having identified loop variants with desired properties from our screen, we also
demonstrate modularity in the engineering of Fe domain variants with desired properties
by combining mutant B/C and F/G loops. Grafting in the most specific B/C loop
(H268T/E269D/D270E) into two of the most specific F/G loops (P329A/A330L/1332E
and P329A/A330E/1332E) yield combined variants with additive properties - enhanced
FcyRIIIA 176F binding and decreased FcyRIIB binding. These combined variants have A/I
ratios that rival if not exceed those of previously reported variants and display virtually
no binding to the inhibitory receptor, and thus should prove valuable tools for parsing out
the contributions of individual FcyRs to therapeutic response, as well as in the design of
therapeutic antibodies with optimal FcyR binding properties.
Materials and Methods
Loop saturation mutagenesis library construction. See Chapter 4, Materials &
Methods.
Oligonucleotides. See Chapter 4, Materials & Methods.
Library screening. Library screening was performed using the cell surface secretion
assay (CeSSA) (34). Briefly, pooled loop libraries were grown in SD-CAA (2% glucose,
0.67% yeast nitrogen base, 0.54% Na2HPO4, 0.86% NaH2PO4-H 20, 0.5% casein amino
acids) to an OD 60 0 of~ 5, and then induced in YPG (2% galactose, 2% peptone, 1% yeast
extract, 0.54% Na2HPO 4, 0.86% NaH2PO 4-H2O) for 12 hrs at 20 'C. Following this pre-
induction phase, yeast were labeled with fluorescein-PEG-NHS (Laysan Bio) and re-
induced in YPG containing 15% PEG (w/v) at 20 'C for 36 hrs. Cells were then washed
with PBS containing 0.1% (w/v) BSA (PBS/BSA).
For the first two rounds of screening, pooled libraries were subjected to multiple,
successive depletion steps for FcyRIIB binding followed by positive enrichment for
FcyRIIIA 176F binding on magnetic beads. Depletion was carried out by incubating pooled
libraries with biotinylated hFcyRIIB preloaded onto streptavidin magnetic beads
(Invitrogen) for 2 h at 4 0C with rotation, followed by magnetic separation, removal of
unbound yeast, and subsequent further incubation of the depleted population again with
FcyRIIB-coated magnetic beads, for a total of four successive depletions. Following the
final depletion step, positive enrichment for binding to hFcyRIIIA176F was performed by
incubating the unbound yeast population with FcyRIIIA 176F coated magnetic beads,
magnetic separation, washing with PBS/BSA, and elution and propagation of captured
clones by growth of captured magnetic beads in SD-CAA supplemented with
penicillin/streptomycin at 30 'C. Starting with the third round of screening, following
successive depletion, yeast were labeled with biotinylated hFcyRIIIA176F preloaded onto
streptavidin-Alexa 647 (Invitrogen). The subpopulations were sorted on either a BD
FACSAria (Becton Dickinson) or a MoFlo Cell Sorter (Cytomation Inc) and collected
cells grown in SD-CAA supplemented with penicillin/streptomycin (Invitrogen), for three
100
additional rounds of screening (five rounds in total). Library populations were labeled
for FACS sorting at increasingly stringent concentrations of FcyRIIIA 176F tetramer as
follows: round four (800 pM), round five (200 pM).
Cloning and Site Directed Mutagenesis. See Chapter 4, Materials & Methods.
Characterization of HEK-secreted Fc mutants. Unless otherwise noted, Fc variants
were transiently transfected into HEK 293F cells (Invitrogen) in a 6-well plate format.
Cell culture supernatants were loaded onto fluorescein-conjugated yeast overnight at
4 'C; yeast were then washed with PBS/BSA, labeled with biotinylated FcyR preloaded
onto streptavidin-Alexa 647 at 4 'C for > 2 hrs, and analyzed by flow cytometry.
Labeling with 10 ptg/ml Protein A-Alexa 647 (Invitrogen) was performed as a separate
IgG loading control for all samples. FcyR labeling fluorescence for individual variants
was normalized by the surface IgG loading of a variant relative to that of wild-type IgG,
as determined by relative Protein A-Alexa 647 labeling. There was strong agreement
(within 10% difference) between this approach to signal normalization and gating on a
population of cells to give similar surface loading signals.
Antibodies and recombinant proteins. See Chapter 4, Materials & Methods.
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Sequences of B/C and F/G loop variants enriched for FcyRIIIA176 F specific-binding.
Sequences of B/C loop clones enriched after the fourth (A) and more stringent fifth (B) rounds of
screening. Sequences of F/G loop clones enriched after the fourth (C) and more stringent fifth
(D) rounds of screening. Dashes represent the same residue as the wild-type sequence. Numbers
in parentheses represent the number of times a particular clone was present in the population
sequenced.
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Relative binding of clones enriched from screen. B/C loop (A) and F/G loop (B) 4m5.3 Fc
variants enriched for FcyRIIIA17 6F specific binding from the yeast-based screen were expressed
from HEK cells and assayed for relative binding to FcyRIIIA176F and FcyRIIB compared to wild-
type (WT). Fluorescein-labeled yeast were incubated with cell culture supernatants, labeled with
5.0 nM of streptavidin Alexa 647 FcyR tetramer, and then cells analyzed by flow cytometry.
Data represent the average of two trials, normalized by the relative IgG surface loading of a given
variant compared to wild-type, as determined by a separate Protein A 647 loading control.
Dashes represent the same residue as the wild-type sequence.
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Mutational analysis of lead clones enriched for FcyRIHA specific binding. Relative binding
of the previously described D270E variant compared to the enriched B/C loop clone
H268T/E269D/D270E and the component double mutants H268T/D270E and E269D/D270E.
Similarly, relative binding of the previously described S239D/A330L/I332E variant and the F/G
loop only clones A330L/I332E, P329A/A330L/I332E, and P329A/A330L/1332E to (A)
FcyRIIIA176F, (B) FcyRIIB, and (C) FcYRIIA131R. 4m5.3 Fc variants were expressed from HEK
cells, purified with Protein A agarose, and 20 sg/ml of antibody loaded onto fluorescein-labeled
yeast. Yeast were labeled with streptavidin Alexa 647 FcyR tetramers and analyzed by flow
cytometry. Data represent the average of two trials; similar IgG surface loading of a given
variant compared to wild-type was confirmed by a separate Protein A 647 loading control.
104
FcyRIfAIT'F
I
1000-
aoo -
a00-
400-
200-
0-
250-
200-
150-
100-
FcyRlA131R
WT TDE ALE AE*E TDE/ TDE/
AL*E AE*E
Effect of loop grafting of candidate B/C and F/G loop variants. Relative binding of
H268T/E269D/D270E (TDE), P329A/A330L/1332E (AL*E), P329A/A330E/1332E (AE*E), and
the loop grafted versions TDE/AL*E and TDE/AE*E to (A) FcyRIIIA 7 6F, (B) FcyRIIB, and (C)
FcyRIIA131R. 4m5.3 Fc variants were expressed from HEK cells, purified with Protein A agarose,
and 20 gg/ml of antibody loaded onto fluorescein-labeled yeast. Yeast were labeled with
streptavidin Alexa 647 FcyR tetramers and analyzed by flow cytometry. Data represent the
average of two trials; similar IgG surface loading of a given variant compared to wild-type was
confirmed by a separate Protein A 647 loading control.
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Figure 5.5 (c, d)
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Figure 5.5 (legend)
Comparison of engineered variants to published variants. Relative binding of the engineered,
loop-grafted FcyRIIIA-specific variants compared to previously published variants, to (A)
I131R ( RI 176FFceyRILA" , (B) FcyRIIB, (C) FcyRIIIA"', and (D) FcyRIIIA' . Variant abbreviations:
WT
TDE/AL*E
TDE/AE*E
*DE/AL*E
*DE/AE*E
Macrogenics
Genentech
Xencor
wild-type
H268T/E269D/D270E/P329A/A330L/1332E
H268T/E269D/D270E/P329A/A330E/1332E
E269D/D270E/P329A/A330/1332E
E269D/D270E/P329A/A330E/1332E
F243L/R292P/Y300LN305I/P396L
S298A/E333A/K334A
S239D/A330L/1332E
4m5.3 Fc variants were expressed from HEK cells, purified with Protein A agarose, and 20 ig/ml
of antibody loaded onto fluorescein-labeled yeast. Yeast were labeled with streptavidin Alexa
647 FcyR tetramers and analyzed by flow cytometry. Data represent the average of two trials;
similar IgG surface loading of a given variant compared to wild-type was confirmed by a separate
Protein A 647 loading control.
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Figure 5.6
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Comparison of engineered variants to published variants. Data from Figure 5.5, replotted to
illustrate the changes in FcyRIIIA 76F and FcyRIIB binding in comparison to wild-type Fc. Data
represent the points at 5 nM FcyRIIIA176F tetramer and 10 nM FcyRIIB tetramer. Additional
abbreviations from Figure 5.5 legend: Mac (Macrogenics), Gen (Genentech), Xen (Xencor).
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